

## **Longitudinal Multi-omic Immune Profiling Reveals Age-Related Immune Cell Dynamics in Healthy Adults**

Qiuyu Gong<sup>1\*</sup>, Mehul Sharma<sup>1\*</sup>, Emma L. Kuan<sup>1</sup>, Marla C. Glass<sup>1</sup>, Aishwarya Chander<sup>1</sup>, Mansi Singh<sup>1</sup>, Lucas T. Graybuck<sup>1</sup>, Zachary J. Thomson<sup>1</sup>, Christian M. LaFrance<sup>1</sup>, Samir Rachid Zaim<sup>1</sup>, Tao Peng<sup>1</sup>, Lauren Y. Okada<sup>1</sup>, Palak C Genge<sup>1</sup>, Katherine E. Henderson<sup>1</sup>, Elisabeth M. Dornisch<sup>1</sup>, Erik D. Layton<sup>1</sup>, Peter J. Wittig<sup>1</sup>, Alexander T. Heubeck<sup>1</sup>, Nelson M. Mukuka<sup>1</sup>, Julian Reading<sup>1</sup>, Charles R. Roll<sup>1</sup>, Veronica Hernandez<sup>1</sup>, Vaishnavi Parthasarathy<sup>1</sup>, Tyanna J. Stuckey<sup>1</sup>, Blessing Musgrove<sup>1</sup>, Elliott Swanson<sup>1</sup>, Cara Lord<sup>1</sup>, Morgan D.A. Weiss<sup>1</sup>, Cole G. Phalen<sup>1</sup>, Regina R. Mettey<sup>1</sup>, Kevin J. Lee<sup>1</sup>, John B. Johanneson<sup>1</sup>, Erin K. Kawelo<sup>1</sup>, Jessica Garber<sup>1</sup>, Upaasana Krishnan<sup>1</sup>, Megan Smithmyer<sup>2</sup>, E. John Wherry<sup>4,5</sup>, Laura Vella<sup>5,6</sup>, Sarah E. Henrickson<sup>5,6</sup>, Mackenzie S. Kopp<sup>1</sup>, Adam K. Savage<sup>1</sup>, Lynne A. Becker<sup>1</sup>, Paul Meijer<sup>1</sup>, Ernest M. Coffey<sup>1</sup>, Jorg J. Goronzy<sup>7</sup>, Cate Speake<sup>2</sup>, Thomas F. Bumol<sup>1</sup>, Ananda W. Goldrath<sup>1</sup>, Troy R. Torgerson<sup>1</sup>, Xiao-jun Li<sup>1</sup>, Peter J. Skene<sup>1\*\*</sup>, Jane H. Buckner<sup>3</sup>, Claire E. Gustafson<sup>1\*\*</sup>

<sup>1</sup> Allen Institute for Immunology, Seattle, WA, USA

<sup>2</sup> Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA USA

<sup>3</sup> Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA USA

<sup>4</sup> Department of Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

<sup>5</sup> Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

<sup>6</sup> Department of Pediatrics, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

<sup>7</sup> Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

\* These authors contributed equally to this work

\*\*corresponding authors. Claire E. Gustafson: [claire.gustafson@alleninstitute.org](mailto:claire.gustafson@alleninstitute.org), Peter J. Skene: [peter.skene@alleninstitute.org](mailto:peter.skene@alleninstitute.org)

## Summary

The generation and maintenance of protective immunity is a dynamic interplay between host and environment that is impacted by age. Understanding fundamental changes in the healthy immune system that occur over a lifespan is critical in developing interventions for age-related susceptibility to infections and diseases. Here, we use multi-omic profiling (scRNA-seq, proteomics, flow cytometry) to examine human peripheral immunity in over 300 healthy adults, with 96 young and older adults followed over two years with yearly vaccination. The resulting resource includes scRNA-seq datasets of >16 million PBMCs, interrogating 71 immune cell subsets from our new Immune Health Atlas. This study allows unique insights into the composition and transcriptional state of immune cells at homeostasis, with vaccine perturbation, and across age. We find that T cells specifically accumulate age-related transcriptional changes more than other immune cells, independent from inflammation and chronic perturbation. Moreover, impaired memory B cell responses to vaccination are linked to a Th2-like state shift in older adults' memory CD4 T cells, revealing possible mechanisms of immune dysregulation during healthy human aging. This extensive resource is provided with a suite of exploration tools at <https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/> to enhance data accessibility and further the understanding of immune health across age.

## 1 **Introduction**

2 Tracking the dynamics of the healthy immune landscape over the lifespan is  
3 critical for understanding susceptibility to infections, responses to vaccines, and the  
4 onset of immune-related diseases that occur differentially across the aging spectrum.  
5 While many studies on immune health and aging utilize single snapshots of the immune  
6 system to infer common features of this aging process, (Sayed et al. 2021; Whiting et al.  
7 2015; Sparks et al. 2024) the function of immune cells is always dictated by some  
8 element of time. The innate immune compartment (i.e., monocytes, neutrophils) is  
9 heavily engaged in rapid and stochastic responses (hours to days) whereas the  
10 adaptive immune compartment (T cells, B cells) mediates slower but more durable  
11 memory responses (days to years). Indeed, recent studies focused on longitudinal  
12 monitoring in the context of infection, vaccination and homeostasis have offered a  
13 unique view of the global age-associated changes in the immune system and provided  
14 deeper insights into the dynamic interplay of immunity with exposures over time.  
15 (Fourati et al. 2022; Van Phan et al. 2024; Alpert et al. 2019)

16 The wide-spread implementation of single-cell RNA sequencing (scRNA-seq)  
17 has revolutionized our ability to dissect the complexities of the immune system, enabling  
18 deep interrogation of individual immune cells. (Terekhova et al. 2023; Mogilenko,  
19 Shchukina, and Artyomov 2022) Combining scRNA-seq, and other high-plex methods,  
20 with longitudinal sampling offers unprecedented insights into the ongoing adaptation of  
21 the immune system at a single cell level and interactions between immune cells and  
22 their surrounding microenvironment. Notably, memory T cells and B cells play pivotal  
23 roles in long-term immunity, collectively orchestrating responses to pathogens and  
24 vaccines throughout one's life. Memory responses in mice and humans can be  
25 maintained for decades, in part through self-renewal. (Soerens et al. 2023; Akondy et al.  
26 2017; Fuertes Marraco et al. 2015) However, in long-term mouse studies, memory T  
27 cells progressively accumulated unique transcriptional programs over time. (Soerens et  
28 al. 2023) Similarly, transcriptional alterations in the T cell compartment of humans have  
29 been increasingly recognized as a feature of aging (H. Zhang et al. 2022; Thomson et  
30 al. 2023; Moskowitz et al. 2017), associated with diminished immune responses and  
31 increased vulnerability to infections among older adults. (Gustafson et al. 2020)  
32 However, the breadth, variation and, in turn, stability of these changes across the entire  
33 peripheral immune compartment and their link to concurrent age-related immune  
34 dysfunction in people, including impaired vaccine-specific antibody production and a  
35 higher propensity for chronic viral re-activation, are not fully elucidated.

36 Here, we longitudinally profiled the peripheral immune system in 96 healthy  
37 young and older adults over 2 years, in the homeostatic state and following annual  
38 immune perturbation induced by influenza vaccination. Employing scRNA-seq, high-  
39 dimensional plasma proteomics, and spectral flow cytometry to samples collected at 8-

40 10 time points per donor, we investigated the molecular and cellular mechanisms  
41 underlying broad age-related changes in immune responsiveness. This effort generated  
42 a human peripheral immune cell scRNA-seq reference dataset composed of over 13.7  
43 million peripheral blood mononuclear cells (PBMCs) from our longitudinal, prospective  
44 cohort and an additional 3.2 million PBMCs from a cross-sectional follow-up cohort of  
45 234 healthy adults. Our study uniquely demonstrates that T cell subsets in older adults  
46 maintain distinct transcriptional programming compared to those in young adults, with  
47 reprogramming in early T cell subsets accumulating over time, independent of  
48 inflammation and changes induced by chronic CMV infection. Memory B cell subsets,  
49 while exhibiting minimal age-related transcriptional reprogramming at homeostasis,  
50 demonstrate significantly altered responses to vaccine-induced perturbation in older  
51 adults. We further reveal that altered memory B cell responses correlate with memory  
52 CD4 T cell reprogramming towards a Th2-skewed state across age, providing insights  
53 into mechanisms of age-related immune dysregulation and unique targets for  
54 therapeutic intervention and disease prevention in older adults.

55

## 56 **Results**

57

### 58 **Generation of a high-resolution healthy peripheral immune cell atlas for** 59 **application across human immune studies.**

60 A critical step in understanding the immune landscape in healthy people across  
61 age is defining robust immune cell types within a tissue of interest. A number of  
62 references exist for labeling of human immune cells within peripheral blood using  
63 scRNA-seq datasets (Domínguez Conde et al. 2022; Terekhova et al. 2023; Hao et al.  
64 2021), however none of these references collectively met our input criteria. These  
65 criteria included 1) use of many donors to account for immune composition  
66 heterogeneity, 2) large number of cells sequenced per donor to allow detection of rarer  
67 subsets, and 3) a broad age range of donors to account for age-specific variation. Thus,  
68 we began by building a new human immune cell atlas, based on scRNA-seq data we  
69 generated from peripheral blood mononuclear cells (PBMCs) of more than 100 healthy  
70 donors ranging from 11 to 65 years (yrs) of age (n=108, **Figure 1A**). Cohort details are  
71 provided in **Supplemental Table 1**. The cell numbers after quality control and doublet  
72 removal averaged more than 15,000 cells per donor (mean: 16,867 cells, range of 25-  
73 75 quartiles: 15074-18264 cells, sample-specific metrics are included in **Supplemental**  
74 **Table 1**), generating a final dataset of 1.82 million high-quality PBMCs from healthy  
75 people across age. From these data, we used a hierarchical label strategy,  
76 unsupervised clustering and distinct immune-based marker genes to define 9 cell  
77 subsets at level 1, 29 subsets at level 2 and 71 subsets at level 3, that further  
78 encompasses broad features of age, sex and cytomegalovirus (CMV) infection. (**Figure**  
79 **1B, 1C**) Level 3 includes characterization of 35 T cell, 11 B cell, 7 monocyte, 6 natural

80 killer (NK) and 12 other subsets including dendritic cells and hematopoietic precursors.  
81 **(Figure 1D, see Methods)**. The number of cells used to generate this atlas allowed  
82 resolution of smaller, more unique subsets such as CD27<sup>-</sup> TBX21<sup>+</sup> effector B cells and  
83 the recently described population of circulating KLRC2<sup>+</sup> CD8-alpha alpha T cells.  
84 (Thomson et al. 2023) Further details on our Human Immune Health Atlas and immune  
85 cell subsets can be found at [https://apps.allenimmunology.org/aifi/resources/imm-](https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/)  
86 [health-atlas/](https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/). We utilized this high-quality, high-resolution human peripheral immune cell  
87 atlas for labeling cells in all subsequent scRNA-seq analyses presented here, providing  
88 consistent comparison of immune subsets across RNA and multi-modal single cell  
89 sequencing datasets.

90

### 91 **Changes in the homeostatic programming of T cell subsets accumulate over the** 92 **course of age, independent of systemic inflammation.**

93 To-date, there are limited longitudinal studies focused on understanding the  
94 dynamics of the immune cell landscape across healthy age, as these types of studies  
95 require two different time scales of “aging”; 1) comparison of donors of different ages  
96 and 2) repeat sampling of individual donors over time. To address this gap, we  
97 prospectively recruited a cohort of 49 young adults (25-35 yrs of age at enrollment) and  
98 47 older adults (55-65 yrs of age at enrollment) and followed them longitudinally over  
99 the course of 2 years. **(Figure 2A)** During this time course, donors received 2 seasonal  
100 influenza vaccinations and up to 10 total blood draws. Vaccine-related blood draws  
101 were collected at 0, 7 and 90 days post-vaccination (“Flu Vax” series). A similar 0, 7 and  
102 90 day time course was collected but with no vaccination administration (“No Vax”  
103 series), as well as additional “stand-alone” visits to account for seasonal variation.  
104 These time points were designed to enable comparison of age-related differences in the  
105 immune landscape that occur during homeostatic maintenance as well as during  
106 vaccine-induced perturbation. CMV serology was additionally performed to allow  
107 comparison of the impact of immune perturbation induced by chronic viral infection.  
108 PBMCs and plasma were collected at each blood draw for in-depth immune profiling  
109 assays that included scRNA-seq, spectral flow cytometry, O-link plasma proteomics and  
110 influenza-specific serology. Extensive clinical data was collected on donors at each  
111 blood draw and is available for detailed exploration at  
112 <https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/vis/clinical/>.  
113 Basic cohort demographics, including age, sex, CMV infection status, and sample  
114 information are detailed in **Supplemental Table 1**.

115 Age-related changes in the circulating proteome are well-described (Argentieri et  
116 al. 2023; Whiting et al. 2015), however there are conflicting results regarding the  
117 association between circulating markers of inflammation and age. Thus, we first  
118 investigated proteomic changes in our healthy adult cohort via our Olink dataset. We  
119 found 69 proteins differentially expressed at baseline between young and older adults

120 (65 increased and 4 decreased with  $\text{padj} < 0.05$ ), including previously described markers  
121 including CXCL17 and WNT9A at baseline. (**Figure 2B, 2C**) (Argentieri et al. 2023)  
122 Notably, no significant increase in classic inflammatory proteins TNF, IL-6, IL-1B or a  
123 more recently described age-related marker IL-11 (Widjaja et al. 2024) were detected  
124 over time in older adults. (**Figure S1A**) The observed age-related alterations were also  
125 maintained over time, with a similar pattern of protein differences observed a year later.  
126 (**Figure S1B, S1C**) Thus, we find circulating hallmarks of healthy age persist in the  
127 absence of systemic inflammation.

128 We next interrogated the cellular landscape of healthy immune aging utilizing our  
129 scRNA-seq dataset. To build the reference dataset for this study, all scRNA-seq data  
130 collected from our cohort was compiled and cells were labeled via our new Human  
131 Immune Health Atlas. After cell label transfer, post-transfer doublet exclusion, and  
132 clean-up, the resulting longitudinal immune health dataset consisted of >13.7 million  
133 PBMCs. Similar to the atlas dataset, the cell numbers per sample averaged more than  
134 15,000 cells per donor per time point (mean: 15,886 cells, range of 25-75 quartiles:  
135 14,153-18,032 cells, sample-specific metrics are included in **Supplemental Table 1**).  
136 The final dataset includes more than 3 million T cells, 1.2 million B cells, 1.1 million NK  
137 cells, 2.4 million monocytes, 123,020 dendritic cells, and 10,431 hematopoietic  
138 precursors, building a rich resource to interrogate age-related immune changes at high-  
139 resolution in many immune cell subsets simultaneously.

140 A consistent hallmark of immune aging is the loss of naïve CD8 T cells. We  
141 began by examining cellular composition as a key feature of the aging process in this  
142 reference dataset. We found significant age-related compositional changes in 16  
143 immune cell subsets, including decreased frequencies of core naïve CD8 T cells at  
144 baseline ( $\text{padj} = 8.6\text{e-}12$ ) in older adults that is a hallmark feature of immune aging.  
145 (**Supplemental Table 2**) To further explore features of homeostatic immune aging, we  
146 next focused on examining transcriptional profiles across all 71 immune cell subsets  
147 defined by our Human Immune Health Atlas. For these analyses, we performed pseudo-  
148 bulk differential gene analyses comparing young and older adults at baseline (“Flu Year  
149 1 Day 0”), controlling for sex and CMV as potential confounding factors. We found that  
150 T cell subsets were the main immune cells that exhibited transcriptional changes with  
151 age. (**Figure 2D**) Consistent with previous T cell-focused studies (Thomson et al. 2023;  
152 Moskowitz et al. 2017), T cell subsets early in differentiation showed the highest number  
153 of age-related differentially expressed genes (DEGs), with naïve > central memory >  
154 effector memory subsets. Of note, few transcriptional changes were observed in other,  
155 non-T cell subsets and many subsets exhibited no age-related changes in their  
156 transcriptome. To confirm this observation, we ran a cross-sectional analysis on  
157 samples collected one year later (“Flu Year 2 Day 0”) and found similar results. (**Figure**  
158 **S1D, S1E**) Age-related changes were also distinct from those found in immune subsets  
159 when directly assessing broad immune perturbations caused by CMV infection and

160 influenza vaccination. (**Figure S1F**) Indeed, many transcriptional differences in B cell  
161 subsets were found with vaccination, highlighting that the lack of age-related differences  
162 in this adaptive immune compartment is unlikely a technical artifact due to lower B cell  
163 numbers in the peripheral blood. While T cell subsets also demonstrated the most  
164 significant changes in frequencies with age, the transcriptional changes did not directly  
165 correspond with compositional changes in the subsets. (**Figure 2E**) Indeed, core naive  
166 CD4 T cells show the most transcriptional changes (N=331 DEGs) with no significant  
167 difference in frequency ( $p_{adj}=0.65$ ), whereas core naive CD8 T cells show both  
168 transcriptional (N=182 DEGs) and frequency changes with age. Thus, during  
169 homeostasis, T cells are the peripheral immune cell subset most transcriptionally and  
170 compositionally altered by age, with few transcriptional changes observed in other  
171 innate and adaptive immune compartments.

172 The homeostatic aging process has been linked with transcriptional variation  
173 however the actual stability of immune cell programming across age is unknown. To  
174 further determine the stability of age-related transcriptional changes in T cells, we  
175 analyzed the longitudinal transcriptional changes (over the course of 600 days) in the 8  
176 immune cell subsets with the most differentially expressed genes. These subsets  
177 included core naive CD8 T cells, core naive CD4 T cells, central memory CD8 T cells  
178 (N=185 DEGs), GZMK+CD27+ effector memory CD8 T cells (N=67 DEGs), naive CD4  
179 Tregs (N=158 DEGs), central memory CD4 T cells (N=161 DEGs), GZMB-CD27-  
180 effector memory CD4 T cells (N=56 DEGs) and GZMB-CD27+ effector memory CD4 T  
181 cells (N=69 DEGs). To interrogate the overall maintenance of transcriptional profiles  
182 with age, we developed upregulated and downregulated RNA-based composite scores  
183 as summary metrics of age-related differential gene expression specific to each of these  
184 subsets. (**Figure S2A**) Applying these metrics to each donor, we found consistent age-  
185 related transcriptome changes in young and older adults (adjusted  $p<0.05$  for all  
186 subsets). (**Figure S2B**) There was also a significant correlation between age metric  
187 across each of the 8 T cell subsets within an individual (**Figure 2F**), implying that  
188 transcriptional changes occur uniformly across the T cell compartment of an individual  
189 with age. Moreover, older adults consistently maintained differential age metrics  
190 compared with young adults over a 2-year period. (**Figure 2G, 2H, Figure S2C, S2D**).  
191 These data collectively indicate that age-related transcriptional differences are  
192 maintained over time in age-susceptible T cell subsets.

193 To further collectively confirm that these proteomic, compositional and  
194 transcriptional changes accumulate over the course of homeostatic aging, we acquired  
195 a second cross-sectional cohort of paired PBMC and serum samples from healthy  
196 adults ( $n=234$ ), with a continuous age range from 40 to 90+ years of age (Whiting et al.  
197 2015), and again performed deep immune profiling. (**Figure 3A**) Basic cohort  
198 demographics, including age, sex, and CMV infection, as well as sample assay  
199 information are detailed in **Supplemental Table 1**. Proteomic analysis revealed

200 circulating proteins altered with healthy age continuously accumulate across the aging  
201 spectrum in the absence of systemic inflammation, evidenced by the lack of association  
202 with TNF, IL6, IL1B and IL11 with chronological age. (**Figure 3B**) We further utilized the  
203 scRNA-seq data to build a follow-up reference of more than 3.2 million PBMCs of  
204 similar quality as our original datasets (**Figure 3C**; see Methods). Initial examination of  
205 the 71 cell subsets confirmed the expected hallmarks of immune aging, including a  
206 decrease in core naive CD8 T cells (slope: -7.6, pval=5.3e-26) and a modest, although  
207 not significant, increase of CM CD4 T cells (slope: 2.12, pval=1.4e-01) across age.  
208 (**Figure 3D, 3E**) To better understand the dynamics of the transcriptional programming  
209 across age, we applied our previously described summary metrics of age-related  
210 differential gene expression (“transcriptional age” metric). We found a continuous  
211 increase in the age metric for upregulated genes across the 8 age-susceptible subsets  
212 from people 40 to 65 years of age. (**Figure 3F**) Notably, the upregulated RNA age  
213 metric consistently plateaued after 65 years of age across all subsets. Conversely, the  
214 age metric for down-regulated genes demonstrated the opposing pattern, remaining  
215 relatively stable from 40-65 then rapidly decreasing from 65-90 yrs of age. (**Figure 3G**)  
216 This suggests that up- and down-regulated genes within immune cells have different  
217 dynamics in adults above 65 years of age and may be distinct from those occurring  
218 between 40-65 years of age. To further investigate the functional implications of these  
219 changes, we assessed the overlap between DEGs in these 8 subsets to find commonly  
220 targeted genes; identifying 26 gene down-regulated and 36 gene up-regulated with age  
221 that were consistent in at least 4 subsets. Common age-related genes included  
222 increasing genes associated with effector differentiation (e.g., *PTGER2*) and  
223 intracellular signaling responses (e.g., *SESN3*, *ANHAK*) (**Figure 3H**), as well as  
224 decreasing genes associated with cell state polarization (e.g., *IL16*) and apoptosis (e.g.,  
225 *STK17A*). (**Figure 3I**) Collectively, these data demonstrate that age-related changes in  
226 the immune landscape affect T cell subsets early in differentiation and coordinated  
227 changes occur progressively over the course of age, independent from markers of  
228 systemic inflammation.

### 229 230 **The immune landscape induced by chronic CMV infection is stable over time and** 231 **distinct from aging.**

232 Cytomegalovirus (CMV) is thought to contribute to low-grade inflammation by  
233 inducing chronic immune stimulation over time. However, the impact of age on the  
234 cellular and molecular landscape induced by CMV infection has yet to be fully  
235 elucidated. To assess the overall impact of CMV on the immune landscape of our  
236 healthy adult cohort, the cell frequencies and transcriptomes of the 71 immune cell  
237 subsets were compared in CMV<sup>+</sup> and CMV<sup>-</sup> individuals (CMV<sup>+</sup> n = 44; CMV<sup>-</sup> n = 52). We  
238 found 6 cell subsets to be significantly impacted by CMV infection (i.e., with greater than  
239 5 DEGs and cell frequency differences of adj p<0.05). (**Figure 4A**) In particular, we



240 found increased frequencies of KLRF1<sup>+/</sup>-GZMB<sup>+</sup> EM CD8 T cells (KLRF1<sup>+</sup> padj=0.002;  
241 KLRF1<sup>-</sup> padj =3.9e-10 ), KLRF1<sup>-</sup>GZMB<sup>+</sup> EM CD4 T cells (padj=1.5e-18), GZMK<sup>+</sup> CD27<sup>+</sup>  
242 EM CD8 T cells (adjusted p= 0.02), KLRF1<sup>+</sup>  $\gamma\delta$  T cells (padj = 1.8e-07) and adaptive NK  
243 cells (padj = 1.2e-08) in CMV<sup>+</sup> compared with CMV<sup>-</sup> individuals. Immune cell subsets  
244 with CMV-related cell frequency increases also displayed more prominent  
245 transcriptional changes, including KLRF1<sup>+/</sup>-GZMB<sup>+</sup> EM CD8 T cells (KLRF1<sup>+</sup> N=23  
246 DEGs; KLRF1<sup>-</sup> N=56 DEGs), KLRF1<sup>-</sup>GZMB<sup>+</sup> EM CD4 T cells (N=8 DEGs), and adaptive  
247 NK cells (N=63 DEGs). These findings were confirmed in our larger, follow-up cohort  
248 (CMV<sup>+</sup> n=136; CMV<sup>-</sup> n=98). (**Figure S3A**) Thus, we determined specific innate and  
249 adaptive immune cell subsets commonly expanded in chronic CMV infection, regardless  
250 of age.

251 We next compared the age-associated stability of compositional changes  
252 observed in CMV<sup>+</sup> people, focused on these 6 commonly expanded immune cell  
253 subsets. No age-related differences in the frequencies of the more terminal-like effector  
254 T cell subsets, KLRF1<sup>+/</sup>-GZMB<sup>+</sup> EM CD8 T cells, in CMV<sup>+</sup> adults were observed both at  
255 baseline and over a two-year period (**Figure 4B, Figure S3B**), possibly due to the  
256 relatively 'younger' nature of our healthy cohort (less than 65 yrs of age). There was,  
257 however, a significant decrease in adaptive NK cells (padj=0.01) in CMV<sup>+</sup> older adults  
258 compared with CMV<sup>+</sup> young adults, which was maintained over a two-year period  
259 (**Figure 4B**). To confirm this age-related decrease of adaptive NK cells, we performed  
260 spectral flow cytometry on 24 young (CMV<sup>+</sup> n=12; CMV<sup>-</sup> n=12) and 24 older (CMV<sup>+</sup>  
261 n=12; CMV<sup>-</sup> n=12) adults. While both CMV<sup>+</sup> young and older adults showed expanded  
262 adaptive NKs compared with CMV<sup>-</sup> individuals, adaptive NK cells (defined as  
263 KLRC2<sup>+</sup>CD57<sup>+</sup>CD56dimCD16<sup>+</sup> cells (Dogra et al. 2020; Lopez-Vergès et al. 2011)) had  
264 a lower frequency in older CMV<sup>+</sup> adults compared to young CMV<sup>+</sup> adults. (**Figure 4C,**  
265 **4D**) We also noted a trending decrease in expression of KLRC2 (a.k.a., NKG2C) on  
266 adaptive NK cells from CMV<sup>+</sup> older individuals. (**Figure 4E**) Thus, age modestly impacts  
267 the composition of the CMV-mediated immune landscape in healthy adults.

268 We then evaluated the impact of CMV infection on age-related differences in the  
269 transcriptome of age-susceptible T cell subsets (identified in **Figure 2**), using our RNA  
270 age metric. Consistent with CMV infection mainly impacting more terminal effector T cell  
271 subsets, no significant differences in the age-related transcriptional profiles of these 8 T  
272 cell subsets between CMV<sup>+</sup> and CMV<sup>-</sup> young or older adults were found (**Figure S3C**,  
273 p>0.05 for all 8 subsets), indicating that chronic viral infection does not accelerate  
274 transcriptional age in T cell subsets early in differentiation. We assessed how age  
275 impacts the transcriptional changes induced by chronic CMV infection in all immune cell  
276 subsets, comparing CMV-induced gene expression in young and older adults  
277 separately. From these analyses, we found that adaptive NKs and KLRF1<sup>-</sup>GZMB<sup>+</sup> EM  
278 CD8 T cells displayed the most transcriptional changes with CMV infection in young  
279 adults, however these changes were much less pronounced in older adults at baseline.

280 **(Figure S3D)** The number of CMV-induced DEGs in adaptive NKs were also found to  
281 be consistently reduced in older adults one year later (Flu Year 2 Day 0). **(Figure S3E)**  
282 Moreover, a subset of CMV-induced genes in adaptive NKs of young adults exhibited  
283 overall lower expression in older adults, including *KLRC2*. **(Figure 4F)** In particular,  
284 *ZBTB38*, a newly defined marker gene of the adaptive NK population (Rebuffet et al.  
285 2024), was decreased, both consistently over time in CMV<sup>+</sup> older adults compared with  
286 CMV<sup>+</sup> young adults **(Figure 4G)**, as well as decreasing in expression in CMV<sup>+</sup> subjects  
287 across age in our follow-up cohort, reaching similar expression to CMV<sup>-</sup> subjects in  
288 advanced age. **(Figure 4H)** Thus, the changes in the transcriptional landscape induced  
289 by CMV infection are relatively independent of age, however the adaptive NK subset  
290 uniquely exhibits a stably altered transcriptional state suggestive of lower activation in  
291 older adults.

292 CMV infection may have systemic effects on the immune system as well, thus we  
293 evaluated the impact of CMV and age on the circulating proteome. Although we did not  
294 find any significant different proteins between CMV<sup>+</sup> and CMV<sup>-</sup> individuals at a global  
295 level, we took advantage of the one young adult that seroconverted from CMV<sup>-</sup> to CMV<sup>+</sup>  
296 during our longitudinal study to identify select proteins that are induced by CMV  
297 infection. CMV-induced proteins were determined via strict criteria of being expressed at  
298 low levels during the CMV uninfected phase but had a persistent increase after infection  
299 of at least 1.5-fold higher than the highest pre-infection level. We identified 10 proteins  
300 that met these criteria. **(Figure 4I)** We next evaluated whether there was a significant  
301 difference in expression levels of these 10 proteins in CMV<sup>+</sup> vs. CMV<sup>-</sup> individuals from  
302 our full longitudinal cohort. We found that 4 of the proteins (FCRL6, FCRL3, KLRD1,  
303 GZMH) were significantly increased in chronic CMV infection **(Figure 4J, not shown)**,  
304 independent of age. Additionally, higher expression of GZMH in CMV<sup>+</sup> individuals was  
305 maintained over time and showed significant CMV-related differences in our follow-up  
306 cohort, again independent of age. **(Figure 4K)** To further link these proteomic changes  
307 back to the observed changes in cellular composition, we evaluated which immune cell  
308 subsets transcriptionally express GZMH. GZMH was expressed the highest in GZMB<sup>+</sup> T  
309 cell subsets and adaptive NKs **(Figure 4L, 4M)**, linking CMV-related immune cell  
310 expansion with the circulating proteome. Together, these data demonstrate that CMV  
311 infection stably alters the immune cell landscape in adults, with age primarily altering  
312 adaptive NK cells in healthy CMV<sup>+</sup> adults.

313

### 314 **Age-related alterations in B cell responses to vaccine-induced perturbation are** 315 **maintained over time.**

316 It is well-known that age also has a major impact on the ability of an individual to  
317 make effective, long-lasting antibody responses to vaccination, linked to alterations in  
318 the B cell compartment (Wang et al. 2019; Frasca et al. 2016), however less is known  
319 about the impact of age on broader B cell responses to vaccine-induced perturbation

320 (i.e., bystander activation) in healthy adults. To study these broad responses, we first  
321 binned individuals into their specific “flu vaccine year” to account for variation in  
322 seasonal flu vaccine composition (e.g., flu strains, adjuvants) that may impact cell  
323 responses, identifying 26 young and 42 older adults receiving the same vaccine in the  
324 year. (**Figure 5A**) Then we assessed whether our sub-cohort was generally  
325 representative of other aging cohorts, examining total level of influenza vaccine-specific  
326 IgG antibodies as well as the functional capacity of vaccine-specific antibodies using a  
327 custom hemagglutination inhibition (HAI) MSD assay at day 0 and day 7 post-  
328 vaccination. We additionally evaluated antibody responses against a vaccine neo-  
329 antigen (B/Washington strain; **Figure 5B, 5C**) and a vaccine recall antigen (B/Phuket  
330 strain; **Figure 5D, 5E**). Consistent with previous aging studies, the functional antibody  
331 response (HAI) to a recall antigen was significantly lower in older adults. (**Figure 5E**)  
332 However, the neo-antigen HAI responses were similar between young and older adults  
333 (**Figure 5C**), as were total vaccine-specific IgG levels for both neo- and recall antigens.  
334 (**Figure 5B, 5D**) Thus, these data consistently demonstrate that age impacts vaccine-  
335 specific antibody responses and uniquely indicate that memory, but not naïve, B cell  
336 responses are preferentially impaired with age.

337 In our previous analyses, we observed memory B cell subsets had the most  
338 transcriptional changes after vaccination. (**Figure S1F**) Thus, we utilize our high-  
339 resolution scRNA-seq dataset to further explore the impact of vaccine-induced  
340 perturbation on the composition and transcriptome of these subsets with age. We  
341 assessed age-related frequencies of plasma cells pre- and post-vaccination, as a  
342 classic cellular read-out of vaccine-specific responses in the periphery. Like the total flu-  
343 specific IgG responses, we found both young and older adults exhibited similar  
344 increased in plasma cells post-vaccination. (**Figure 5F**) We also observed similar  
345 increases in frequencies for multiple memory B cell subsets, including CD27<sup>-</sup> effector B  
346 cells, CD27<sup>+</sup> effector B cells and CD95<sup>+</sup> memory B cells, independent of age. However,  
347 core memory and type 2 polarized B cell subsets had reduced expansion in older  
348 adults. (**Figure 5F**) We further confirmed these frequency changes via flow cytometry  
349 analysis on a subset of donors, demonstrating strong correlations between RNA- and  
350 flow-based B cell subset frequencies. (**Figure S4A**) Thus, while there was no alteration  
351 in the vaccine-specific expansion of plasma cells with age, we observe a broader, age-  
352 related limitation in expansion of memory B cell subsets with age.

353 To further assess broad memory B cell responses to vaccination, we interrogated  
354 transcriptional profiles at day 7 post-vaccination for enrichment of activation-related  
355 signaling pathways. Plasma cells exhibited pathway enrichment indicative of higher  
356 activation, whereas core memory B cells demonstrated lower MYC-related activation in  
357 older adults that aligned with their limited expansion with age. (**Figure S4B**) Similar to  
358 core memory, CD27<sup>+</sup> effector B cells also lower enrichment in pathways associated  
359 with activation in older adults (e.g., MYC pathway, adjusted p value: 3.68-08, NES:

360 2.02). (**Figure S4C, S4D**) CD27<sup>-</sup> effector B cells also exhibited reduced ROS-  
361 associated signaling in older adults (adjusted p value: 0.04, NES: 1.77; **Figure 5G**),  
362 which has previously been linked to flu vaccine responsiveness. (Nellore et al. 2023)  
363 This reduction was observed at multiple different time points over the course of  
364 vaccination. (**Figure 5H**) Moreover, this effector B cell subset in older adults shows  
365 lower expression of genes associated with functional effector memory B cells (Nellore et  
366 al. 2023) (**Figure 5I, 5J**), including lineage-defining genes *FCRL5*, *CD19*, *MAS4A1*, and  
367 *ITGAX*, as well as activation genes like *ZEB2*, *TBX21*, *XBP1*, *S100A10*, *DAPP1*, and  
368 *BATF*. Collectively, these data indicate that older adults have broad alterations in the  
369 compositional and transcriptional B cell responses to vaccine-induced perturbation.

370 A key feature of effective B cell responses to flu vaccination is the production of  
371 class-switched immunoglobulin G (IgG) antibodies. Thus, we assessed whether the  
372 CD27<sup>-</sup> effector B cell subset displayed altered isotype composition post-vaccination.  
373 Notably, older adults displayed significantly lower expression of IgG genes (e.g.,  
374 *IGHG1*) as well as higher *IGHD* and *IGHM* expression than young adults in CD27-  
375 effector B cells. (**Figure 5K**) The reduction in *IGHG* genes was found in both year 1 and  
376 year 2 flu vaccination series, demonstrating that there is a consistent decline in class-  
377 switch responses overall with age. To further confirm these data, we assessed IgG  
378 expression by the effector memory B cell subset via spectral flow cytometry using the B  
379 cell annotation strategy from Glass, et. al., 2020. (Glass et al. 2020) We found that  
380 frequency of IgG<sup>+</sup> CD27<sup>-</sup> effector B cells was significantly lower in older adults both at 0  
381 and 7 days post-vaccination than young adults (**Figure 5L, 5M**). Moreover, the CD27-  
382 effector population also expressed less surface CD19 in older adults (**Figure 5N**),  
383 corresponding to their age-related gene expression profiles. Thus, CD27<sup>-</sup> effector B  
384 cells, an important subset in response to flu vaccination, display lower IgG class-  
385 switching and express less lineage-defining surface markers with age. Together, these  
386 data reveal that multiple memory B cell subsets have altered age-related responses to  
387 vaccine-induced perturbation that could play a role in reduced antibody functionality in  
388 older adults.

### 389 390 **Accumulation of a Th2-like state in memory CD4 T cells is associated with age- 391 related B cell dysregulation.**

392 Poor memory B cell activation, altered immunoglobulin class switching and  
393 reduced vaccine-specific antibody functionality in older adults suggests there may be  
394 alterations in memory T cell helper capacity with age. However, our initial flow  
395 cytometry-based analysis found no differences in the frequencies of activated T  
396 follicular helper cells (defined as ICOS<sup>+</sup>CD38<sup>+</sup>PD1<sup>+</sup>CXCR5<sup>+</sup> CD4 T cells) at day 7 post-  
397 vaccination between young and older adults. (**Figure S5A**) These data, in tandem with  
398 similar frequencies of vaccine-induced plasma cells, indicate that the general process of  
399 antigen-specific activation and expansion are likely maintained with age. Thus, we

400 determine if age-related molecular reprogramming of CM CD4 T cells, which are one of  
401 the most transcriptionally altered memory T cell subsets with age (**Figure 2**), could  
402 influence the type of helper functions these cells provide to B cells. Initial analyses of  
403 the overall 'helper' programming found that the Tfh transcriptional signature within the  
404 CM CD4 T cells decreased with age, (**Figure S5B**) with a main Tfh-defining marker  
405 CXCR5 expression decreased in CM CD4 T cells from older adults. (**Figure S5C**) This  
406 decrease was confirmed by a consistent loss of CXCR5 expression across age in our  
407 follow-up cohort. (**Figure S5D**) We next used CellPhoneDB (Efremova et al. 2020) to  
408 interrogate receptor-ligand interactions. (**Figure 6A**) Notably, we found that CM CD4 T  
409 cells from older adults displayed reduced predicted interactions with core memory B  
410 cells, including a key complex for B cell activation CD40LG:CD40. (**Figure 6B**) This  
411 reduced interaction exhibited similar decreases in these receptor-ligand interactions at  
412 year 2 (**Figure S5E**) and stemmed from a loss of CD40LG in CM CD4 T cells (**Figure**  
413 **S5F**), but not CD40 in core memory B cells, in older adults. (**Figure S5G**) This was  
414 confirmed in our follow-up cohort, which showed steadily decreasing expression of  
415 CD40LG in CM CD4 T cells, but not CD40 in core memory B cells, across age. (**Figure**  
416 **6C**) Thus, CM CD4 T cells exhibit a lower transcriptional propensity for providing direct  
417 help to memory B cells with age.

418 In addition to direct interactions, T cells can mediate B cell responses through  
419 indirect, cytokine-mediated interactions based on their help state (i.e., Th1, Th2, Th17).  
420 (Olatunde, Hale, and Lamb 2021) Using recently described scRNA-seq-based cell state  
421 signatures (Yasumizu et al. 2024), we examined the Th1, Th2 and Th17-like state of  
422 CM CD4 T cells with age. From these analyses, we found that older adults exhibited a  
423 significant skewing towards a Th2-like state compared to young adults in CM CD4 T  
424 cells that was stably maintained over time. (**Figure 6D, 6E**) Moreover, our follow-up  
425 cohort confirmed a continuous increase in the Th2-like state in CM CD4 T cells across  
426 age. (**Figure 6F**) Neither Th1- or Th17-like states changed significantly with age or over  
427 time in the CM CD4 T cells. To further confirm the association between age and the  
428 development of Th2-like state, we utilized our previously published tri-modal TEA-seq  
429 data to interrogate TF activity within CM CD4 T cells from children (11-13 yrs) and older  
430 adults (55-65 yrs). (**Figure S5H**) (Thomson et al. 2023) Consistent with the elevation in  
431 a Th2-like transcriptional state, activity of the Th2-associated TF GATA3 ( $p=0.00016$ )  
432 was significantly higher in CM CD4 T cells in older adults (**Figure 6G**). The activity of  
433 TBX21, the main Th1-associated TF, did not change with age. GATA3 activity also  
434 directly correlated with the RNA-based Th2-like cell state metric within this independent  
435 dataset. (**Figure 6H**) Consistent with higher GATA3 activity and a Th2-like state, older  
436 adults also exhibited increased chromatin openness within the IL4 locus, a GATA3-  
437 regulated gene. (**Figure 6I**) Activity of the classical Th2 cytokine-driven TF STAT6 was  
438 not elevated in CM CD4 T cell with age (**Figure S5I**), nor was there increased openness  
439 at the STAT6-regulated gene IL4R. (**Figure S5J**) The elevation in GATA3 activity in

440 older adult CM CD4 T cells was in the absence of any notable increase in protein levels  
441 of circulating Th2-polarizing cytokines IL-4, IL-5 and IL-13 across age. (**Figure S5K,**  
442 **S5L**) Thus, we find that the molecular programming of memory CD4 T cells become  
443 gradually skewed towards a GATA3-related transcriptional state with age that is not  
444 directly reflected on a systemic level in the circulating proteome.

445 The age-related transcriptional changes in memory T cells collectively indicate  
446 the potential for altered B cell activation (via CD40LG:CD40 interactions) and B cell  
447 class switching (via Th2 state) in response to vaccine-induced perturbation in older  
448 adults. To further link stable homeostatic alterations in memory T cells with broad  
449 vaccine-induced memory B cell dysregulation with age, we interrogated the association  
450 of Th2 and T follicular helper cell states in CM CD4 T cells with chronological age,  
451 transcriptional age (RNA age metrics), baseline T cell functionality and broad vaccine-  
452 induced B cell responses in our longitudinal cohort. (**Figure 7A**) Consistent with the  
453 direction of gene expression, Th2 and Tfh states correlated with up- and down-  
454 summary metrics respectively (Th2:RNA Age metric (up)  $pval=0.02$ ,  $\rho=0.28$ ; Tfh:RNA  
455 Age metric (down)  $pval=1.02e-10$ ,  $\rho=0.796$ ). Th2 and Tfh states were commonly  
456 associated with many features of T cell functionality and B cell responses (albeit in  
457 opposite directions), including CM CD4 T cell CXCR5 expression and core memory B  
458 cell activation pathways. Notably, the Th2 state of CM CD4 T cells specifically and  
459 inversely correlated with CD40L:CD40 interactions between CM CD4 T cells and core  
460 memory B cells (confirmed in our follow-up cohort ( $pval=0.011$ ,  $\rho=-0.17$ )), as well as  
461 the magnitude of change in HAI inhibition (i.e., functional antibody responses) at day 7  
462 post-vaccination. (**Figure 7B**) Additional, we find IGHG4 expression in Core memory  
463 and CD95 memory B cell post-vaccination positively correlated with Th2 state of CM  
464 CD4 T cells but not Tfh programming (**Figure 7A, 7B**), which is consistent with  
465 cytokines mediating changes in B cell antibody isotype. These data build a model in  
466 which memory CD4 T cells progressively lose intrinsic helper potential in tandem with  
467 developing a Th2 state across age that leads to reduced memory B cell activation,  
468 altered class-switching and less function antibody production in older adults. Taken  
469 together, exploration of our new, large-scale longitudinal immune health resource  
470 reveals novel cellular and molecular features of the healthy immune system connected  
471 to its responsiveness to acute and chronic perturbation with age.

472

## 473 **Discussion**

474 In this study, we sought to uncover key features of the healthy peripheral immune  
475 system that accompany the aging process. By applying our newly developed Human  
476 Immune Health Atlas to two unique healthy adult cohorts (one longitudinal and one  
477 cross-sectional), we conducted an in-depth analysis of the molecular and cellular  
478 landscape of the immune compartment at homeostasis and in response to acute and  
479 chronic perturbation. This effort resulted in a high-resolution scRNA-seq resource  
480 comprising over 16 million peripheral immune cells from more than 300 healthy

481 individuals aged 25 to 90 years. Additionally, this resource includes paired plasma  
482 proteomics and spectral flow cytometry, offering complex, multi-dimensional insights  
483 into human immunity across health and aging. We also provide a suite of interactive  
484 data exploration tools at [https://apps.allenimmunology.org/aifi/insights/dynamics-imm-](https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/)  
485 [health-age/](https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/) to enable researchers easier, open access to this extensive human immune  
486 health resource and to further facilitate new immunological discoveries and applications.

487 The longitudinal nature of this study allows us to gain insight into immune cell  
488 programming at baseline, its stability over time and its broad alterations with acute and  
489 chronic perturbation. Remarkably, we observe long-term stability in homeostatic  
490 programming of many immune cell subsets is unaffected by age. While the  
491 programming of T cell subsets early in their differentiation was significantly altered by  
492 age, there was also little to no age-related effects on the more terminal T cell subsets,  
493 contrasting inflammatory, senescent or exhausted T cell features commonly associated  
494 in advanced aging studies. (Zhu et al. 2023; Mogilenko et al. 2021; Elyahu et al. 2019)  
495 Recent mouse studies have demonstrated a gradual shift towards an exhausted-like  
496 transcriptional state within the memory T cell compartment over a decade of antigenic  
497 re-challenge. (Soerens et al. 2023) However, our study's finding on the stability of  
498 certain features of transcriptional programming up to 65 years of age suggest this  
499 transition towards exhaustion may occur in more advanced age (i.e., >65 yrs of age). It  
500 also implies that homeostatic maintenance during early adulthood may be a more  
501 nuanced relationship between a cell's lifespan, its programming, and the  
502 microenvironment it inhabits (i.e., lymph nodes) in the absence of overt disease. (Ural et  
503 al. 2022; Cakala-Jakimowicz, Kolodziej-Wojnar, and Puzianowska-Kuznicka 2021)

504 CMV infection is another immunologic challenge intertwined with age - implicated  
505 to cause chronic immune activation and to modulate protective immunity in adults.  
506 (Furman et al. 2015; Picarda and Benedict 2018) Similar to previous observations, we  
507 found that individuals of all ages infected with CMV had a marked shift in their  
508 peripheral immune landscape, highlighted by the acquisition of terminally differentiated  
509 cytotoxic T cell subsets and adaptive NK cells. (Bayard et al. 2016; Wertheimer et al.  
510 2014; Schlub et al. 2011) Moreover, these changes were stable over the 2-year course  
511 of the study, neither displaying transient nor cumulative reprogramming as one may  
512 expect from reoccurring or continuous immune perturbation. Adaptive NK cells show an  
513 age-associated decrease in frequencies and subtle transcriptional differences  
514 suggestive of reduced activation in older adults. The gradual age-related reduction in  
515 ZBTB38 and KLRC2 expression, key population-defining markers recently described for  
516 'NK3' cells (Rebuffet et al. 2024), also indicates potential plasticity in the epigenetic  
517 programming of this immune cell subset across age. (Lau et al. 2018; Rückert et al.  
518 2022; Schlums et al. 2015) Of note, the recruitment of donors for this study occurred  
519 during the COVID pandemic, a period when exposure to common viruses was  
520 significantly reduced, and thus, the stability of the CMV-induced immune landscape with

521 age in our study may uniquely reflect less immune remodeling by specific and bystander  
522 viral exposure during this period. (Nikolich-Zugich et al. 2020) Given that CMV  
523 activation and exposure significantly impact the success of solid-organ transplantation  
524 (Raglow and Kaul 2023; Kotton 2013; Fishman 2007), further research into the  
525 persistent cytotoxic reshaping of the immune cell landscape and its potential role in  
526 immune-mediated disease risk is warranted.

527 In addition to studying the impact of age on the immune landscape during CMV-  
528 mediated perturbation, we deeply examined acute, age-specific transcriptional  
529 responses of memory B cells to vaccine-induced immune perturbation. A unique feature  
530 of our Immune Health Atlas is the detailed annotation of the B cell compartment, which  
531 revealed novel age-specific transcriptional states in effector and memory B cell subsets  
532 in tandem with changes in vaccine-specific antibody responses during multiple rounds  
533 of immune activation. We found altered transcriptional states post-vaccination in plasma  
534 cells and, interestingly, effector memory B cells, a unique B cell subset associated with  
535 both age and viral infection, from older adults. This CD27<sup>-</sup>CD11c<sup>+</sup>Tbet<sup>+</sup>Zeb2<sup>+</sup> effector  
536 memory B cell subset described had age-associated transcriptional state that  
537 corresponded to reduced activation potential via lower ROS pathway activity and lower  
538 frequencies of IgG<sup>+</sup> cells, highlighting a potential mechanism for reduced protective  
539 responses with age. (Burton et al. 2022). These effector B cells in older adults also  
540 exhibited a reduced gene program affiliated with long-lived humoral responses in the  
541 context of influenza vaccination. (Nellore et al. 2023) Thus, our study reveals a new link  
542 between effector B cells, protective immunity and aging that may contribute to reduced  
543 vaccine efficacy in older adults.

544 Previously, the connection between reduced B cell responses and age-related  
545 transcriptional changes in T cells remained unclear. While evidence suggests CD4 T  
546 cells undergo dysregulation with age, findings regarding the directionality and specific  
547 features of these age-related changes (e.g., Th1 versus Th2 polarization, effector vs  
548 memory function) are conflicting. (Terekhova et al. 2023; Elyahu et al. 2019; Hu et al.  
549 2019) Our findings on the age-related increase in a Th2-like state in central memory  
550 CD4 T cells aligns with recent literature finding elevated CCR4<sup>+</sup> memory T cells in  
551 advanced age (Terekhova et al. 2023) and suggests a mechanism where heightened  
552 Th2 programming impedes T-bet activation in older adults. (Dai et al. 2024; Naradikian  
553 et al. 2016) Indeed, the only described T-bet deficient patient has been shown to have  
554 both high Th2 T cell populations (Yang et al. 2021) and impaired effector B cell  
555 development (Yang et al. 2022), directly linking two of our novel observations in this  
556 study. Furthermore, efficient generation of effector B cells often relies on contact-  
557 dependent help from Tfh cells via CD40 ligand, essential for B cell activation and class  
558 switching. (Nonoyama et al. 1993; Song et al. 2022) This further aligns with an elevated  
559 Th2 state and reduced CD40L expression in central memory CD4 T cells in older adults.  
560 Thus, our study integrates novel mechanisms with established aspects of immune



561 aging, highlighting the dynamic accumulation of features including elevated Th2/Gata3  
562 programming, reduced effector/memory B cell activation, and impaired antibody  
563 functionality across age.

564 In summary, we uncover new insights into the dynamics of the peripheral  
565 immune landscape across age, chronic infection and vaccine-induced perturbation,  
566 underscoring the importance of longitudinal analyses in facilitating a more  
567 comprehensive understanding of age-related immune dysregulation. Our findings  
568 demonstrate that the healthy *stable* state of immune cell subsets change with age and  
569 impacts immune responsiveness, independent from systemic inflammation and chronic  
570 infection. These results have translational implications in the context of designing age-  
571 specific vaccines, treating diseases utilizing immune cell-based treatments (e.g., CAR T  
572 cells) in older adults, and preventing the onset of age-related immunological diseases  
573 such as rheumatoid arthritis.

## Methods

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

#### The Sound Life study cohort

Healthy 25- to 35-year-old and 55- to 65-year-old adult donors were prospectively recruited from the greater Seattle, Washington, USA area as part of the Sound Life Project, a protocol (IRB19-045) approved by the Institutional Review Board (IRB) of the Benaroya Research Institute. All adult participants provided informed consent before participation. Donors were excluded from enrollment if they had a history of chronic disease, autoimmune disease, severe allergy, or chronic infection. All blood samples were collected, processed to PBMCs through a Ficoll-based approach and frozen within 4 hours of blood draw. Plasma samples were processed, aliquoted and frozen within 4 hours of blood draw. Basic demographics are provided in **Supplemental Table 1**.

#### Follow-up cohort

234 paired PBMCs and serum samples were retrospectively selected from a cohort of healthy adults, ages 40 years and older, recruited from the greater Palo Alto, California, USA area, under a protocol approved by Stanford University IRB. (Whiting et al. 2015) All participants provided informed consent before participation and these subsequent studies were approved by the Allen Institute IRB. Basic demographics for the selected follow-up cohort are provided in **Supplemental Table 1**.

### METHOD DETAILS

#### scRNAseq via 10x Genomics v3 chemistry

scRNA-seq was performed on PBMCs from the Sound Life cohort as previously described (Genge et al. 2021), using a modified 10x Genomics Chromium 3' single-cell gene expression assay with Cell Hashing. In brief, PBMCs from the Sound Life cohort were thawed and stained with oligo-tagged antibodies (HTO) allowing for overloading of Chip G (10x Genomics, PN 20000177) wells at 64,000 cells. At cDNA amplification, HTO additive primer was spiked into the cDNA amplification master mix. Following cDNA amplification per the manufacturer's instructions, HTO and GEX cDNA products were separated using SPRI-Select (Beckman Coulter, PN B23319) bead-based cleanup before carrying forward into separate library indexing reactions. Libraries were sequenced on a NovaSeq S4 200 cycle flow cell at Northwest Genomic Center at the University of Washington (<https://nwgc.gs.washington.edu/>). Samples were then computationally resolved and quality-checked using in-house pipelines.

### scRNAseq via 10x Genomics FLEX

PBMCs from our follow-up cohort were thawed per our standard methodology. (Genge et al. 2021) Samples were run in batches of 48 or 64 samples, with mixed age and sex distributions. PBMC bridging controls were included on each batch to allow for cross batch normalization. Viable samples were processed using Chromium Next GEM Single Cell Fixed RNA Sample Preparation Kit (10x Genomics, PN 1000414) according to the 10x Genomics protocol for “Fixation of Cells and Nuclei”. To facilitate high throughput, volumes were scaled from 1 mL to 250  $\mu$ L for plate-based sample preparation and handling. Probe hybridization was completed according to the user guide “Chromium Fixed RNA Profiling Reagent Kits for Multiplexed samples” using the Chromium Fixed RNA Kit, Human Transcriptome, 4 rxns x 16 BC (10x Genomics, PN 1000476). Up to 2 million fixed cells were hybridized per sample. After 16-24 hours of probe hybridization incubation at 42°C, samples were pooled at equivalent cell numbers with 15 samples and a bridging control per pool. Each single cell suspension pool was loaded onto two wells of Chip Q (10x Genomics, PN 2000518) for GEM generation at an overloaded concentration of 400,000 cells. Pre-Amplification PCR and library construction were performed per the manufacturer’s instructions. Final scRNAseq libraries were sequenced using a NovaSeq X 25B 300 cycle flow cell or NovaSeq S4 200 cycle flow cell, depending on total read requirements at either Clinical Research Sequencing Platform at the Broad Institute (<https://broadclinallabs.org/>) or Northwest Genomic Center at the University of Washington (<https://nwgc.gs.washington.edu/>). Samples were then computationally resolved and quality-checked using in-house pipelines.

### Olink Explore 1536

Plasma samples from the Sound Life cohort were run on the Olink Explore 1536 platform, which uses paired antibody proximity extension assays (PEA) and a next generation sequencing (NGS) readout to measure the relative expression of 1472 protein analytes per sample. For plate setup, samples were randomized across plates to achieve a balanced distribution of age and sex. Longitudinal samples from the same participant were run on the same plate. Plasma bridging controls (12-40) were included on each of 6 batches and used for cross-batch normalization.

### Olink Explore 3072

Serum samples were run on the Olink Explore 3072 platform to measure the relative expression of 2943 proteins. Follow-up cohort samples were split across 3 Olink batches with 41 serum bridging controls included across each of the batches for cross-batch normalization. For plate setup, samples were randomized across plates to achieve a balanced distribution of age and sex.

## HCMV serology

Viral serology testing for Human Cytomegalovirus (HCMV) was performed at the University of Washington's Clinical Virology Laboratory in the Department of Laboratory Medicine (<https://depts.washington.edu/uwviro/>). Plasma or serum samples (200  $\mu$ L) were run through the FDA-approved LIAISON® CMV IgG Assay to qualitatively detect CMV IgG class antibodies. Results were reported for each sample as 'Positive' or 'Negative' along with a CMV Ab Screen Index Value ranging from <0.20 to >10.00.

## Adaptive NK Flow Cytometry

One to two million viable PBMCs were plated into wells of a 96-well U-bottom plate. Cells were stained for viability, FC blocked, and then stained with a surface marker antibody cocktail (**Supplemental Table 3**) using BD Brilliant Staining Buffer (BD Biosciences, PN 563794) for 30 minutes at 4°C. The samples were washed, fixed for 60 minutes at room temperature, FC blocked and permeabilized for 10 minutes at room temperature, then stained with an intranuclear antibody staining cocktail for 60 minutes at 4°C using the eBioscience Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher, PN 00-5523-00). After staining, the samples were washed and fixed with Phosphate Buffered Saline solution (PBS) containing 1% paraformaldehyde (PFA) for 15 minutes at 4°C. Finally, the samples were washed and resuspended in PBS before acquisition on a BD Symphony (5L) flow cytometer.

## B-cell Flow Cytometry

PBMCs were rapidly thawed and diluted into 20% Fetal Bovine Serum (FBS) in ATCC-modified RPMI (ThermoFisher Scientific, PN A1049101) and washed with media. Two million viable PBMCs from each donor were seeded into a 96-well V-bottom plate. PBMCs were then incubated with Human TruStain FcX and Purified mouse IgG (BioRad, PN PMP01X) for 10 minutes at room temperature and washed with Wash Buffer (1% FBS in PBS Solution). Cells were incubated with Fixable Viability Stain 510 (BD Biosciences, PN 564406) for 30 minutes at 4°C and then washed. Cells were stained with a filtered antibody cocktail in Wash Buffer for 30 minutes at room temperature (**Supplemental Table 3**) and finally washed with Wash Buffer. Stained PBMCs were immediately resuspended to 10 x10<sup>6</sup> cells/mL in Wash Buffer and acquired on an Aurora 5L flow cytometer (Cytex Biosciences).

## Total Influenza-specific antibody serology

The Meso Scale Discovery (MSD) Prototype Influenza 7-plex Serology Assay protocol measures IgG antibodies in human plasma specific for Influenza vaccine hemagglutinin (HA) antigens: A/Brisbane, A/Hong Kong, A/Michigan, A/Victoria, B/Colorado, B/Phuket, and B/Washington. Briefly, MSD 96-Well 10-Spot multi-array plates coated with seven flu HA antigens were blocked, human plasma samples were diluted 10,000-fold, and

added along with HA reference standards and controls to the plate. Plates were shaken for two hours at 15°C to 25°C, washed, then anti-human IgG antibodies labeled with electrochemiluminescent (ECL) SULFO-TAG were added. Plates were shaken for one additional hour at 15°C to 25°C, washed, then MSD GOLD Read Buffer B was added, and the plates were read on an MSD SECTOR S600 ECL plate reader. Test samples were quantified in AU/mL referenced against specific HA reference standards.

#### Hemagglutination inhibition Influenza-specific antibody serology

The MSD 96-well hemagglutination inhibition (HAI) 9-plex Assay measures neutralizing antibodies in human plasma that block the binding of labeled red blood cell vesicles to trimeric Influenza HA antigens, specific for the following lineages: A/Brisbane, A/Cambodia, A/Guangdong, A/HongKong, A/Kansas, A/Shanghai, A/Wisconsin, B/Phuket, and B/Washington. Briefly, plasma samples were first treated with enzymes to remove interfering sialic acid residues. MSD 96-Well 10-Spot multi-array plates coated with nine trimeric flu HA antigens were blocked and then pretreated human plasma samples diluted 5,000-fold along with HA reference standards were added to the plate. Plates were shaken for two hours at 15°C to 25°C, then red blood cell vesicles labeled with ECL SULFO-TAG were added. Plates were shaken for another two hours at 15°C to 25°C, washed, then MSD GOLD Read Buffer B was added, and the plates were read on an MSD SECTOR S600 ECL plate reader. Test samples were reported as Percent Inhibition, relative to a no-plasma diluent only control. Positive samples show high percent inhibition whereas negative or low samples show low percent inhibition.

#### QUANTIFICATION AND STATISTICAL ANALYSIS

##### Flow Cytometry data analysis and visualization.

Adaptive NK and B cell flow cytometry data analysis consisted of traditional hierarchical gating in FlowJo v10.10 Software. For B cell analysis, total live cell gated data, consisting of all live singlet PBMCs within the experiment, was then downloaded and further processed with the R programming language (<http://www.r-project.org>) and Bioconductor (<http://www.bioconductor.org>) software. Data was transformed with an inverse hyperbolic sine (asinh) transformation with a cofactor of 220. Each marker was scaled to the 99.9th percentile of expression of all cells in the experiment. Total live B cells were over-clustered into 100 clusters using FlowSOM with all informative surface molecules as input. Clusters were then hierarchically clustered based on expression of B cell surface molecules and isotype and finally manually assigned to cell subsets, as described previously. (Glass et al. 2020) B cell subsets were plotted on a UMAP plot using the umap package in R, based on expression of all informative markers and excluding isotype.

### Olink data processing.

Olink's standard data normalization was performed on these datasets. Protein expression values were first normalized across wells using an internal extension control (IgG antibodies conjugated with a matching oligo pair). Plates were then standardized by normalizing to the inter-plate pooled serum or plasma controls run in triplicate on each plate. Data were then intensity normalized across all cohort samples. Final normalized relative protein quantities were reported as log<sub>2</sub> normalized protein expression (NPX) values.

### AIFI Immune Health Atlas (V1) building.

To build our scRNA-seq PBMCs dataset for the AIFI Immune Health Atlas, we utilized data and analysis environments within the Human Immune System Explorer (HISE) system (<https://allenimmunology.org/>) to trace data processing, analytical code, and analysis environments from the original, raw FASTQ data to our final, assembled reference atlas. (Meijer et al. 2024) A graph representation of the analysis trace for this project is available at <https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/reproducibility/>. Additional details are available in our analysis notebooks on Github at <https://github.com/aifimmunology/aifi-healthy-pbmc-reference> and at our website at <https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/>.

### Pipeline processing.

After sequencing, Gene Expression and Hash Tag Oligonucleotide libraries from pooled samples in our pipeline batches were demultiplexed and assembled as individual files for each biological sample as described in (Swanson et al. 2022).

### Data selection from HISE storage.

To assemble the input data for our reference dataset, we selected samples from all subjects in our longitudinal cohort (Sound Life cohort; Young Adult, age 25-35 yrs and Older Adult, age 55-65 yrs) and 16 samples from a previously described healthy pediatric cohort collected at the University of Pennsylvania (age 11-13 yrs (Thomson et al. 2023)). In total, 108 samples were selected for use in our reference (Pediatric, n = 16; Young Adult, n = 47; Older Adult, n = 45), consisting of 2,093,078 cells before additional QC filtering.

### Labeling and doublet detection.

To guide cell type identification, we labeled cells from each sample using CellTypist (v1.6.1)(Domínguez Conde et al. 2022), using the following reference models: Immune\_All\_High (32 cell types), Immune\_All\_Low (98 cell types), and Healthy\_COVID19\_PBMC (51 cell types) by following the approach described in the CellTypist reference documentation at <https://celltypist.org>. We also labeled our cells

using Seurat (v5.0.1) (Hao et al. 2021), which was downloaded from the Zenodo repository (DOI: <https://zenodo.org/doi/10.5281/zenodo.7779016>). For Seurat labeling, we utilized the SCTransform function to transform data to match the reference dataset, then used FindTransferAnchors and MapQuery to assign cell types based on the 3-level cell type labels provided in the reference dataset. We performed doublet detection using the scrublet package (v0.2.3) (Wolock, Lopez, and Klein 2019) implemented in the scanpy.external module of scanpy (v1.9.6).

#### QC filtering.

After assembly of all cells across our 108 samples, we filtered our data against a set of QC criteria designed to remove possible doublets (based on scrublet and high gene detection, > 5,000 genes), low-quality cells (based on low gene detection, < 200 genes), and dying or dead cells (based on mitochondrial UMI content, > 10%). Mitochondrial content was assessed using scanpy by identifying mitochondrial genes (prefixed with "MT-"), and using the scanpy function `calculate_qc_metrics`, as demonstrated in the scanpy tutorials (<https://scanpy-tutorials.readthedocs.io/en/latest/pbmc3k.html>). In total, 140,950 cells were removed (6.73%), and 1,952,128 cells passed QC filtering (93.27%).

#### Clustering and cell subsetting.

After QC filtering, all remaining cells were clustered using a Scanpy workflow (Wolf, Angerer, and Theis 2018) to normalize, log transform, perform PCA, integrate age groups with Harmony (Korsunsky et al. 2019), perform Leiden clustering (Traag, Waltman, and van Eck 2019), and generate 2-dimensional UMAP projections. Clusters were assigned to major cell classes based on marker gene detection. For each cluster, the fraction of cells with detected gene expression for each marker was computed, and clusters meeting a set of cell class-specific criteria were selected for downstream annotation by our domain experts. Clusters from specific cell classes were selected from the full dataset for iterative clustering analysis where necessary to identify cell subpopulations with additional resolution. To assist with cell labeling, marker genes were identified for each cluster at each level of iteration and at each clustering resolution using the scanpy function `scanpy.tl.rank_genes_groups` with the parameter `method = 'wilcoxon'`.

#### Expert annotation of cell types.

Following high-level and iterative clustering, teams of domain experts within the Allen Institute for Immunology examined marker gene expression for clustered datasets and assigned cell type identities to each cluster. As part of this cell type identification exercise, any remaining doublets or low-quality clusters were also identified for later removal during dataset assembly. Cell type nomenclature and multiple levels of cell type resolution were harmonized across our domain experts. We identified 9 low-

resolution cell classes (AIFI\_L1), 29 mid-level cell classes (AIFI\_L2), and 71 high-resolution cell classes (AIFI\_L3). After annotation, cluster labels were transferred to individual cell barcodes to assemble a final set of labels across all cells in our dataset.

Training cell type labeling models.

In order to utilize our cell type atlas to label other PBMCs datasets, we used CellTypist (v1.6.2 (Domínguez Conde et al. 2022)) to generate cell type labeling models. CellTypist utilizes logistic regression as part of its model generation process with a One-vs-Rest (OvR) approach to multiple classes. We slightly modified CellTypist v1.6.2 to also allow the multinomial method provided by the `LogisticRegression()` function in the `scikit.learn` Python package, available at <https://github.com/aifimmunology/multicelltypist>. We used this modified version of CellTypist to train models for each level of our cell type labels using these two approaches. We utilized OvR regression for AIFI\_L1 and AIFI\_L2 labels, and Multinomial regression for AIFI\_L3.

Sound Life scRNA-seq dataset assembly.

To build our longitudinally sampled PBMCs scRNA-seq dataset, we utilized data and analysis environments within the HISE system to trace data processing, analytical code, and analysis environments from raw FASTQ data to a labeled, high-quality final dataset. (Meijer et al. 2024) A graph representation of the analysis trace for this project is available at <https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/reproducibility/>. Additional details are available in our analysis notebooks on Github <https://github.com/aifimmunology/sound-life-scRNA-analysis/> and at our website <https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/>.

Pipeline processing.

After sequencing, Gene Expression and Hash Tag Oligonucleotide libraries from pooled samples in our pipeline batches were demultiplexed and assembled as individual files for each biological sample, as described above for the PBMCs Atlas dataset.

Data Selection.

Input data for our dataset was assembled as described above for the PBMCs Atlas dataset. In total, 868 samples were selected for use in our dataset (Young Adult, n = 49 subjects; n = 418 samples; Older Adult, n = 47 subjects, n = 450 samples), consisting of 15,781,886 cells before additional QC filtering.

Labeling and doublet detection.

To add cell type labels, we utilized CellTypist (v1.6.1) (Domínguez Conde et al. 2022) and the CellTypist models we generated using our Immune Health Atlas dataset at



three levels of cell type resolution (AIFI\_L1, 9 broad cell classes; AIFI\_L2, 29 intermediate cell classes, and AIFI\_L3, 71 high-resolution cell classes) by following the approach described in the CellTypist reference documentation at <https://celltypist.org>. We performed doublet detection the same way as described above for the Atlas. After cell type labeling and doublet detection were performed on each sample, we assembled data, labels, scrublet calls, sample metadata, CMV status, and BMI data across eight sets of samples defined by the cohort, biological sex, and CMV status of subjects to facilitate downstream analyses.

#### QC filtering.

After assembly of all cells across our samples, we filtered our data against the same set of QC criteria as described above for the PBMC Atlas. QC criteria were applied to the dataset in series: cells retained were not identified as a doublet by Scrublet; the percent of total UMIs assigned to mitochondrial regions was  $< 10\%$ ; N genes detected per cell was  $> 200$  and  $< 2,500$ . In total, 951,864 cells were removed (6.03%), and 14,830,022 cells passed QC filtering (93.97%).

#### Clustering, subsetting, and doublet removal.

After QC filtering, all remaining cells were clustered within AIFI\_L2 labels using the scanpy workflow described above for the PBMC Atlas. Clusters were filtered to remove doublets based on marker gene expression. For example, CD4 naive T cell clusters with a high fraction of MS4A1 expression were removed as B cell doublets. We also removed clusters with low gene detection as low quality. Due to their generally lower gene detection, this threshold was not applied to Erythrocyte or Platelet populations. In total, 800,059 cells (5.39%) were removed. 14,029,963 cells (94.61%) were retained for final clean up based on high-resolution AIFI\_L3 labels.

#### Refinement of cell type labels.

After removal of doublets at the AIFI\_L2 cell type resolution, we assembled cells from all samples for each cell type in the high-resolution AIFI\_L3 labeling results. Separately for each cell type, we performed the scanpy data processing procedure described above to enable a final review of cell type labels. Each cell type was examined to identify remaining doublet clusters or clusters of cells that appeared to be mislabeled based on marker gene expression in collaboration with immunological domain experts. During this process, 234,117 cells were removed. 13,795,846 cells were retained for the final reference dataset and downstream analyses.

#### Follow-up Cohort scRNA-seq Reference.

Using our Atlas dataset, all cells in the follow-up cohort were automatically annotated with custom label transfer models built using the CellTypist framework. First, the genes

in the reference dataset were subsampled to match the 18,000 genes in the 10x FLEX scRNA-seq assay. This improved model performance by enhancing recognition of more rare cell populations. Then, three models were built for label transferring – one for each cell labeling level. Finally, the follow-up cohort data was labeled. Dataset cleanup, quality checking, clustering, and visualization were carried out using Scanpy. (Wolf, Angerer, and Theis 2018) Doublets were detected and removed using Scrublet, and minimal inter-batch effects were adjusted in the PCA space for visualization purposes using Harmony. (Korsunsky et al. 2019) After QC filtering, labeling and data clean-up, 3,627,005 cells were retained in the final follow-up reference dataset and used for downstream analyses.

#### Olink Analysis.

The Olink analysis was performed in R using the lme4 package (Bates et al. 2014), applying the design formula:  $\text{NPX}(\text{Bridged}) \sim \text{Age Group} + \text{CMV} + \text{Sex}$ . The comparisons were based on the age group factor. Proteins with an adjusted p-value below 0.05 were considered differentially expressed.

#### Cell frequency comparison from scRNA-seq.

To deal with the constant sum issue on compositional data, we applied the centered log ratio (CLR) transformation on the frequency data for each sample. This transformation was applied to 71 cell types at level 3 labels for each scRNA sample in most frequency comparisons. For comparing switched and non-switched CD27- effector B cell in scRNA data, the CLR transformation was based on total memory B cells at level 3 labels. For the Tfh flow data comparison, the transformation was based on total T cells. In the B cell flow data comparison, the CLR transformation included 9 B cell types and 1 non-B cell type. For the isotype in the B cell flow data experiment, CLR transformation was performed on individual cell types for different isotype. For paired data, we applied the signed-rank Wilcoxon test to the CLR-transformed data. For unpaired data, we used the rank-sum Wilcoxon test on the CLR-transformed data.

#### DEG analysis.

Differential gene analysis was performed using the DESeq2 (version 1.42.0 (Love, Huber, and Anders 2014)) package in R (version 4.3.2). For all comparisons, genes were filtered based on a minimum of 10% non-zero counts in each comparison. Aggregated counts from single cells were used for the comparisons. Several DESeq2 analyses were conducted with default setting:

- For the global baseline comparison of flu year 1 day 0 samples, the design formula used was:  $\text{Aggregated Counts} \sim \text{Age Group} + \text{CMV} + \text{Sex}$ . The contrast was made for each factor.

- For the global flu vaccine and no-vaccine comparisons of year 1 and year 2 samples, the design formula used was: Aggregated Counts ~ Visit + Age Group+ CMV + Sex + Subject. The contrast was made for the visit factor (day 0 vs day 7).
- For the flu response comparison between two age groups for aligned flu years, we included only donors with samples from both the 2020-2021 and 2021-2022 flu seasons. Day 7 samples from both years were used in the analysis. The design formula applied was: Aggregated Counts ~ Flu Year+ Age Group+ CMV + Sex. The contrast was made on the age group factor (young vs older).
- For the CMV comparison, we performed DESeq2 analysis using the design formula: Aggregated Counts ~ Age Group+CMV + Sex. The contrast was made for the CMV factor (positive vs negative).

Genes were considered differentially expressed if their adjusted p-value was below 0.05 and their absolute fold change was greater than 0.1.

#### NMF projection.

We used the NMF projection tool

(<https://github.com/yyoshiaki/NMFprojection/tree/main>) with its precomputed NMF matrix

(<https://github.com/yyoshiaki/NMFprojection/blob/main/data/NMF.W.CD4T.csv.gz>) to compute the NMF scores on Python (version 3.10.13). For each sample, we first subsetted the CD4 T cells and then performed NMF projection according to the recommended workflow. We normalized the different NMF scores based on the mean scores across cells in each cell type at the sample level. For the top genes defining each NMF factor, we extracted the weight of each gene from the precomputed NMF matrix. Genes with higher weights were considered to be more contributive to each factor. We choose the top 20 genes for Tfh NMF factor with highest weight.

#### Cell to cell interaction analysis.

We conducted cell to cell interaction analysis by using CellphoneDB (v5

<https://github.com/ventolab/CellphoneDB>) with method: statistical inference of

interaction specificity on default setting. For each sample, we calculated interactions for CM CD4 T cells and core memory B cells. We retained the interactions with an adjusted p-value below 0.05. For group comparisons, we applied a threshold of  $n > 15$  interaction numbers in two groups (young or older) to filter out the interaction with small numbers of significance.

#### Enrichment analysis.

Two types of enrichment analysis were conducted. For Gene Set Enrichment Analysis (GSEA), using the results from DESeq2, we ranked the genes based on  $-\log_{10}(\text{p-value})$

\*  $\text{sign}(\log_2\text{FoldChange})$  and performed enrichment analysis using the fgsea R package (version 1.28.0). Pathways with an adjusted p-value lower than 0.05 were kept. For Sample Level Enrichment Analysis (SLEA), we used genes that passed the 10% minimal expression threshold as the background gene set and calculated pathway scores for each sample using the leading-edge genes from the fgsea results. At the pseudobulk level, we calculated the mean gene expression with random genes from the background set for each sample, performing 1000 iterations. The z-score was computed as the deviation between the observed mean of leading-edge genes and the mean of the permuted means of random genes, divided by the standard deviation of the permuted means. This deviation was used as the pathway score for each sample.

#### TEA-seq analysis.

TEA-seq datasets were directly downloaded from GEO (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214546>). We performed label transfer, doublet detection, and quality control (QC) based on the RNA module. Label transfer was conducted using Celltypist, based on the models generated from our atlas reference at three levels. We filtered the cells if predicted labels are not T cells. Doublet detection was done using the `scanpy.external.pp.scrublet` function on the RNA module only. Predicted doublets were filtered out before any downstream processes. QC was performed by ensuring that `pct_counts_mito` was below 15%, and `n_genes_by_counts` was either below 2500 or above 200. Cells from the RNA module were matched to those from the ATAC module using original barcodes and well IDs. Any mismatched cells containing only RNA or only ATAC modules were excluded. We performed scATAC analysis on ArchR (version 1.0.2). (Granja et al. 2021) The following steps were executed using the default ArchR workflow: LSI dimensionality reduction, group coverage, identification of reproducible peaks (MACS3) (Y. Zhang et al. 2008), peak matrix construction, motif annotation (cisbp database), background peak construction, deviation matrix, and weight imputation (MAGIC). (van Dijk et al. 2018) The z-scored ChromVar motif matrix was extracted with imputed weights. The motif scores at the sample level were calculated based on the mean score for each cell type within each sample.FOli

#### RESOURCE AVAILABILITY

##### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by lead contacts, Claire E. Gustafson ([claire.gustafson@alleninstitute.org](mailto:claire.gustafson@alleninstitute.org)) and Peter J. Skene ([peter.skene@alleninstitute.org](mailto:peter.skene@alleninstitute.org)).

## Materials availability

This study did not generate new unique reagents.

## Data and code availability

Single-cell RNA-seq data will be deposited at GEO (*to be released upon publication*). Raw single-cell RNA-seq fastq files will be deposited at dbGap and be publicly available as of the date of publication. All original code has been deposited at GitHub and Zenodo: <https://github.com/aifimmunology/aifi-healthy-pbmc-reference/> (<https://zenodo.org/records/13352146>) for generation of the Immune Health Atlas, <https://github.com/aifimmunology/sound-life-scRNA-analysis/> (<https://zenodo.org/records/13352142>) for labeling and assembly of the Sound Life Cohort data, and <https://github.com/aifimmunology/IHA-Figure> (*Zenodo link will be publicly available as of the date of publication*) for downstream analysis and figure generation. All processed data, data objects, and clinical metadata derived from de-identified human subjects is available at the Human Immune System Explorer (HISE) website. This paper also analyzes existing, publicly available data (GEO accession: GSE214546). Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

## Data Visualizations

The following tools are provided to facilitate data exploration and discovery:

**Human Immune Health Atlas:** <https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/>

- 1) ***AIFI Immune Health Atlas UMAP Explorer***. Explore cell subsets and gene expression in a UMAP viewer to display an overview of the entire dataset. <https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/vis/umap/>
- 2) ***AIFI Immune Health Atlas Gene Expression Reference***. A quick reference for gene expression across cell types and age groups. <https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/vis/reference/>
- 3) ***AIFI Immune Health Atlas Clinical Data Explorer***. Flexible visualization of clinical metadata and lab results collected from our Atlas subjects. <https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/vis/clinical/>

## Dynamics of Human Immune Health and Age Resource:

<https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/>

- 4) ***Sound Life Longitudinal Dynamics Explorer***. Explore gene expression and cell type frequency across the longitudinally sampled blood draws within each healthy subject of our longitudinal cohort.

<https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/vis/dynamics/>

- 5) **Sound Life Differential Gene Explorer**. Browse results of pairwise differentially expressed gene (DEG) tests for age, sex, CMV and influenza vaccination between our cohort samples.

<https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/vis/deg/>

- 6) **Sound Life Clinical Data Explorer**. Flexible visualization of clinical metadata and lab results collected from our cohort's subjects.

<https://apps.allenimmunology.org/aifi/insights/dynamics-imm-health-age/vis/clinical/>

**Acknowledgments.** We thank the study participants and the clinical research team at Benaroya Research Institute and Stanford University, including H. Maecker and E. Krishnan, for their effort and dedication to this project research. We thank the Allen Institute founder, P.G. Allen, for his vision, encouragement and support. We also thank H. Gustafson (<https://earlyfutures.com/>) for her collaboration on the Immune Health Atlas color palette and all members of the Allen Institute for Immunology, in particular the facilities and operations teams who helped maintain the productive research environment and the Human Immune System Explorer (HISE) software development team for their constant support. Research reported in this publication was supported by the Allen Institute, Benaroya Research Institute and by National Institute on Aging award K01AG068373 (C.E.G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Overview figures were created with BioRender.com.

**Conflicts of Interest.** A.W.G. serves on the scientific advisory boards of ArsenalBio and Foundry Innovations and is a cofounder of TCura. All other authors declare no conflict of interest.

## **References:**

- Akondy, Rama S., Mark Fitch, Srilatha Edupuganti, Shu Yang, Haydn T. Kissick, Kelvin W. Li, Ben A. Youngblood, et al. 2017. "Origin and Differentiation of Human Memory CD8 T Cells after Vaccination." *Nature* 552 (7685): 362–67.
- Alpert, Ayelet, Yishai Pickman, Michael Leipold, Yael Rosenberg-Hasson, Xuhuai Ji, Renaud Gaujoux, Hadas Rabani, et al. 2019. "A Clinically Meaningful Metric of Immune Age Derived from High-Dimensional Longitudinal Monitoring." *Nature Medicine* 25 (3): 487–95.
- Argentieri, M. Austin, Sihao Xiao, Derrick Bennett, Laura Winchester, Alejo J. Nevado-Holgado, Ashwag Albukhari, Pang Yao, et al. 2023. "Proteomic Aging Clock Predicts Mortality and Risk of Common Age-Related Diseases in Diverse Populations." *BioRxiv*. <https://doi.org/10.1101/2023.09.13.23295486>.

- Bates, Douglas, Martin Mächler, Ben Bolker, and Steve Walker. 2014. "Fitting Linear Mixed-Effects Models Using Lme4." *ArXiv [Stat.CO]*. arXiv. <http://arxiv.org/abs/1406.5823>.
- Bayard, Charles, Hélène Lepetitcorps, Antoine Roux, Martin Larsen, Solène Fastenackels, Virginie Salle, Vincent Vieillard, et al. 2016. "Coordinated Expansion of Both Memory T Cells and NK Cells in Response to CMV Infection in Humans." *European Journal of Immunology* 46 (5): 1168–79.
- Burton, Alice R., Stéphane M. Guillaume, William S. Foster, Adam K. Wheatley, Danika L. Hill, Edward J. Carr, and Michelle A. Linterman. 2022. "The Memory B Cell Response to Influenza Vaccination Is Impaired in Older Persons." *Cell Reports* 41 (6): 111613.
- Cakala-Jakimowicz, Marta, Paulina Kolodziej-Wojnar, and Monika Puzianowska-Kuznicka. 2021. "Aging-Related Cellular, Structural and Functional Changes in the Lymph Nodes: A Significant Component of Immunosenescence? An Overview." *Cells* 10 (11). <https://doi.org/10.3390/cells10113148>.
- Dai, Dai, Shuangshuang Gu, Xi Xia Han, Huihua Ding, Yang Jiang, Xiaou Zhang, Chao Yao, et al. 2024. "The Transcription Factor ZEB2 Drives the Formation of Age-Associated B Cells." *Science* 383 (6681): 413–21.
- Dijk, David van, Roshan Sharma, Juozas Nainys, Kristina Yim, Pooja Kathail, Ambrose J. Carr, Cassandra Burdziak, et al. 2018. "Recovering Gene Interactions from Single-Cell Data Using Data Diffusion." *Cell* 174 (3): 716-729.e27.
- Dogra, Pranay, Chiara Rancan, Wenji Ma, Marta Toth, Takashi Senda, Dustin J. Carpenter, Masaru Kubota, et al. 2020. "Tissue Determinants of Human NK Cell Development, Function, and Residence." *Cell* 180 (4): 749-763.e13.
- Domínguez Conde, C., C. Xu, L. B. Jarvis, D. B. Rainbow, S. B. Wells, T. Gomes, S. K. Howlett, et al. 2022. "Cross-Tissue Immune Cell Analysis Reveals Tissue-Specific Features in Humans." *Science* 376 (6594): eabl5197.
- Efremova, Mirjana, Miquel Vento-Tormo, Sarah A. Teichmann, and Roser Vento-Tormo. 2020. "CellPhoneDB: Inferring Cell-Cell Communication from Combined Expression of Multi-Subunit Ligand-Receptor Complexes." *Nature Protocols* 15 (4): 1484–1506.
- Elyahu, Yehezqel, Idan Hekselman, Inbal Eizenberg-Magar, Omer Berner, Itai Strominger, Maya Schiller, Kritika Mittal, et al. 2019. "Aging Promotes Reorganization of the CD4 T Cell Landscape toward Extreme Regulatory and Effector Phenotypes." *Science Advances* 5 (8): eaaw8330.
- Fishman, Jay A. 2007. "Infection in Solid-Organ Transplant Recipients." *The New England Journal of Medicine* 357 (25): 2601–14.
- Fourati, Slim, Lewis E. Tomalin, Matthew P. Mulè, Daniel G. Chawla, Bram Gerritsen, Dmitry Rychkov, Evan Henrich, et al. 2022. "Pan-Vaccine Analysis Reveals Innate Immune Endotypes Predictive of Antibody Responses to Vaccination." *Nature Immunology* 23 (12): 1777–87.
- Frasca, Daniela, Alain Diaz, Maria Romero, and Bonnie B. Blomberg. 2016. "The Generation of Memory B Cells Is Maintained, but the Antibody Response Is Not, in the Elderly after Repeated Influenza Immunizations." *Vaccine* 34 (25): 2834–40.

- Fuertes Marraco, Silvia A., Charlotte Soneson, Laurène Cagnon, Philippe O. Gannon, Mathilde Allard, Samia Abed Maillard, Nicole Montandon, et al. 2015. “Long-Lasting Stem Cell–like Memory CD8 + T Cells with a Naïve-like Profile upon Yellow Fever Vaccination.” *Science Translational Medicine* 7 (282): 282ra48.
- Furman, David, Vladimir Jovic, Shalini Sharma, Shai S. Shen-Orr, Cesar J. L. Angel, Suna Onengut-Gumuscu, Brian A. Kidd, et al. 2015. “Cytomegalovirus Infection Enhances the Immune Response to Influenza.” *Science Translational Medicine* 7 (281): 281ra43.
- Genge, Palak C., Charles R. Roll, Alexander T. Heubeck, Elliott Swanson, Nina Kondza, Cara Lord, Morgan Weiss, et al. 2021. “Optimized Workflow for Human PBMC Multiomic Immunosurveillance Studies.” *STAR Protocols* 2 (4): 100900.
- Glass, David R., Albert G. Tsai, John Paul Oliveria, Felix J. Hartmann, Samuel C. Kimmey, Ariel A. Calderon, Luciene Borges, et al. 2020. “An Integrated Multi-Omic Single-Cell Atlas of Human B Cell Identity.” *Immunity* 53 (1): 217-232.e5.
- Granja, Jeffrey M., M. Ryan Corces, Sarah E. Pierce, S. Tansu Bagdatli, Hani Choudhry, Howard Y. Chang, and William J. Greenleaf. 2021. “ArchR Is a Scalable Software Package for Integrative Single-Cell Chromatin Accessibility Analysis.” *Nature Genetics* 53 (3): 403–11.
- Gustafson, Claire E., Chulwoo Kim, Cornelia M. Weyand, and Jörg J. Goronzy. 2020. “Influence of Immune Aging on Vaccine Responses.” *The Journal of Allergy and Clinical Immunology* 145 (5): 1309–21.
- Hao, Yuhan, Stephanie Hao, Erica Andersen-Nissen, William M. Mauck 3rd, Shiwei Zheng, Andrew Butler, Maddie J. Lee, et al. 2021. “Integrated Analysis of Multimodal Single-Cell Data.” *Cell* 184 (13): 3573-3587.e29.
- Hu, Bin, Guangjin Li, Zhongde Ye, Claire E. Gustafson, Lu Tian, Cornelia M. Weyand, and Jörg J. Goronzy. 2019. “Transcription Factor Networks in Aged Naïve CD4 T Cells Bias Lineage Differentiation.” *Aging Cell* 18 (4): e12957.
- Korsunsky, Ilya, Nghia Millard, Jean Fan, Kamil Slowikowski, Fan Zhang, Kevin Wei, Yuriy Baglaenko, Michael Brenner, Po-Ru Loh, and Soumya Raychaudhuri. 2019. “Fast, Sensitive and Accurate Integration of Single-Cell Data with Harmony.” *Nature Methods* 16 (12): 1289–96.
- Kotton, C. N. 2013. “CMV: Prevention, Diagnosis and Therapy.” *American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 13 Suppl 3 (February): 24–40; quiz 40.
- Lau, Colleen M., Nicholas M. Adams, Clair D. Geary, Orr-El Weizman, Moritz Rapp, Yuri Pritykin, Christina S. Leslie, and Joseph C. Sun. 2018. “Epigenetic Control of Innate and Adaptive Immune Memory.” *Nature Immunology* 19 (9): 963–72.
- Lopez-Vergès, Sandra, Jeffrey M. Milush, Brian S. Schwartz, Marcelo J. Pando, Jessica Jarjoura, Vanessa A. York, Jeffrey P. Houchins, et al. 2011. “Expansion of a Unique CD57<sup>+</sup>NKG2Chi Natural Killer Cell Subset during Acute Human Cytomegalovirus Infection.” *Proceedings of the National Academy of Sciences of the United States of America* 108 (36): 14725–32.
- Love, Michael I., Wolfgang Huber, and Simon Anders. 2014. “Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2.” *Genome Biology* 15 (12): 550.



- Meijer, Paul, Nicole Howard, Jessica Liang, Autumn Kelsey, Sathya Subramanian, Ed Johnson, Paul Mariz, et al. 2024. "Provide Proactive Reproducible Analysis Transparency with Every Publication." *ArXiv [Cs.CE]*. arXiv. <http://arxiv.org/abs/2408.09103>.
- Mogilenko, Denis A., Irina Shchukina, and Maxim N. Artyomov. 2022. "Immune Ageing at Single-Cell Resolution." *Nature Reviews. Immunology* 22 (8): 484–98.
- Mogilenko, Denis A., Oleg Shpynov, Prabhakar Sairam Andhey, Laura Arthur, Amanda Swain, Ekaterina Esaulova, Simone Brioschi, et al. 2021. "Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as Conserved Hallmark of Inflammaging." *Immunity* 54 (1): 99-115.e12.
- Moskowitz, David M., David W. Zhang, Bin Hu, Sabine Le Saux, Rolando E. Yanes, Zhongde Ye, Jason D. Buenrostro, Cornelia M. Weyand, William J. Greenleaf, and Jörg J. Goronzy. 2017. "Epigenomics of Human CD8 T Cell Differentiation and Aging." *Science Immunology* 2 (8). <https://doi.org/10.1126/sciimmunol.aag0192>.
- Naradikian, Martin S., Arpita Myles, Daniel P. Beiting, Kenneth J. Roberts, Lucas Dawson, Ramin Sedaghat Herati, Bertram Bengsch, et al. 2016. "Cutting Edge: IL-4, IL-21, and IFN- $\gamma$  Interact To Govern T-Bet and CD11c Expression in TLR-Activated B Cells." *Journal of Immunology* 197 (4): 1023–28.
- Nellore, Anoma, Esther Zumaquero, Christopher D. Scharer, Christopher F. Fucile, Christopher M. Tipton, R. Glenn King, Tian Mi, et al. 2023. "A Transcriptionally Distinct Subset of Influenza-Specific Effector Memory B Cells Predicts Long-Lived Antibody Responses to Vaccination in Humans." *Immunity* 56 (4): 847-863.e8.
- Nikolich-Žugich, Janko, Luka Čicin-Šain, Donna Collins-McMillen, Sarah Jackson, Annette Oxenius, John Sinclair, Christopher Snyder, Mark Wills, and Niels Lemmermann. 2020. "Advances in Cytomegalovirus (CMV) Biology and Its Relationship to Health, Diseases, and Aging." *GeroScience* 42 (2): 495–504.
- Nonoyama, S., D. Hollenbaugh, A. Aruffo, J. A. Ledbetter, and H. D. Ochs. 1993. "B Cell Activation via CD40 Is Required for Specific Antibody Production by Antigen-Stimulated Human B Cells." *The Journal of Experimental Medicine* 178 (3): 1097–1102.
- Olatunde, Adesola C., J. Scott Hale, and Tracey J. Lamb. 2021. "Cytokine-Skewed Tfh Cells: Functional Consequences for B Cell Help." *Trends in Immunology* 42 (6): 536–50.
- Picarda, Gaëlle, and Chris A. Benedict. 2018. "Cytomegalovirus: Shape-Shifting the Immune System." *Journal of Immunology* 200 (12): 3881–89.
- Raglow, Zoe, and Daniel R. Kaul. 2023. "A New Antiviral Option for Cytomegalovirus Prevention After Kidney Transplant." *JAMA: The Journal of the American Medical Association*.
- Rebuffet, Lucas, Janine E. Melsen, Bertrand Escalière, Daniela Basurto-Lozada, Avinash Bhandoola, Niklas K. Björkström, Yenan T. Bryceson, et al. 2024. "High-Dimensional Single-Cell Analysis of Human Natural Killer Cell Heterogeneity." *Nature Immunology*, July. <https://doi.org/10.1038/s41590-024-01883-0>.


- Rückert, Timo, Caleb A. Lareau, Mir-Farzin Mashreghi, Leif S. Ludwig, and Chiara Romagnani. 2022. "Clonal Expansion and Epigenetic Inheritance of Long-Lasting NK Cell Memory." *Nature Immunology* 23 (11): 1551–63.
- Sayed, Nazish, Yingxiang Huang, Khiem Nguyen, Zuzana Krejciova-Rajaniemi, Anissa P. Grawe, Tianxiang Gao, Robert Tibshirani, et al. 2021. "An Inflammatory Aging Clock (IAge) Based on Deep Learning Tracks Multimorbidity, Immunosenescence, Frailty and Cardiovascular Aging." *Nature Aging* 1 (7): 598–615.
- Schlub, Timothy E., Joseph C. Sun, Senta M. Walton, Scott H. Robbins, Amelia K. Pinto, Michael W. Munks, Ann B. Hill, Laurent Brossay, Annette Oxenius, and Miles P. Davenport. 2011. "Comparing the Kinetics of NK Cells, CD4, and CD8 T Cells in Murine Cytomegalovirus Infection." *Journal of Immunology* 187 (3): 1385–92.
- Schlums, Heinrich, Frank Cichocki, Bianca Tesi, Jakob Theorell, Vivien Beziat, Tim D. Holmes, Hongya Han, et al. 2015. "Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function." *Immunity* 42 (3): 443–56.
- Soerens, Andrew G., Marco Künzli, Clare F. Quarnstrom, Milcah C. Scott, Lee Swanson, J. J. Locquiao, Hazem E. Ghoneim, et al. 2023. "Functional T Cells Are Capable of Supernumerary Cell Division and Longevity." *Nature* 614 (7949): 762–66.
- Song, Wenzhi, Olivia Q. Antao, Emily Condiff, Gina M. Sanchez, Irene Chernova, Krzysztof Zembrzuski, Holly Steach, et al. 2022. "Development of Tbet- and CD11c-Expressing B Cells in a Viral Infection Requires T Follicular Helper Cells Outside of Germinal Centers." *Immunity* 55 (2): 290-307.e5.
- Sparks, Rachel, Nicholas Rachmaninoff, William W. Lau, Dylan C. Hirsch, Neha Bansal, Andrew J. Martins, Jinguo Chen, et al. 2024. "A Unified Metric of Human Immune Health." *Nature Medicine*, July. <https://doi.org/10.1038/s41591-024-03092-6>.
- Swanson, Elliott, Julian Reading, Lucas T. Graybuck, and Peter J. Skene. 2022. "BarWare: Efficient Software Tools for Barcoded Single-Cell Genomics." *BMC Bioinformatics* 23 (1): 106.
- Terekhova, Marina, Amanda Swain, Pavla Bohacova, Ekaterina Aladyeva, Laura Arthur, Anwasha Laha, Denis A. Mogilenko, et al. 2023. "Single-Cell Atlas of Healthy Human Blood Unveils Age-Related Loss of NKG2C+GZMB-CD8+ Memory T Cells and Accumulation of Type 2 Memory T Cells." *Immunity* 56 (12): 2836-2854.e9.
- Thomson, Zachary, Ziyuan He, Elliott Swanson, Katherine Henderson, Cole Phalen, Samir Rachid Zaim, Mark-Phillip Peabworth, et al. 2023. "Trimodal Single-Cell Profiling Reveals a Novel Pediatric CD8 $\alpha$ <sup>+</sup> T Cell Subset and Broad Age-Related Molecular Reprogramming across the T Cell Compartment." *Nature Immunology* 24 (11): 1947–59.
- Traag, V. A., L. Waltman, and N. J. van Eck. 2019. "From Louvain to Leiden: Guaranteeing Well-Connected Communities." *Scientific Reports* 9 (1): 5233.
- Ural, Basak B., Daniel P. Caron, Pranay Dogra, Steven B. Wells, Peter A. Szabo, Tomer Granot, Takashi Senda, et al. 2022. "Inhaled Particulate Accumulation

- with Age Impairs Immune Function and Architecture in Human Lung Lymph Nodes.” *Nature Medicine* 28 (12): 2622–32.
- Van Phan, Hoang, Alexandra Tsitsiklis, Cole P. Maguire, Elias K. Haddad, Patrice M. Becker, Seunghye Kim-Schulze, Brian Lee, et al. 2024. “Host-Microbe Multiomic Profiling Reveals Age-Dependent Immune Dysregulation Associated with COVID-19 Immunopathology.” *Science Translational Medicine* 16 (743): eadj5154.
- Wang, Wei, Qiong Chen, Lauren A. Ford-Siltz, Leah C. Katzelnick, Gabriel I. Parra, Hyo Sook Song, Russell Vassell, and Carol D. Weiss. 2019. “Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-Year Vaccination.” *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America* 68 (12): 2067–78.
- Wertheimer, Anne M., Michael S. Bennett, Byung Park, Jennifer L. Uhrlaub, Carmine Martinez, Vesna Pulko, Noreen L. Currier, Dragana Nikolich-Žugich, Jeffrey Kaye, and Janko Nikolich-Žugich. 2014. “Aging and Cytomegalovirus Infection Differentially and Jointly Affect Distinct Circulating T Cell Subsets in Humans.” *Journal of Immunology* 192 (5): 2143–55.
- Whiting, Chan C., Janet Siebert, Aaron M. Newman, Hong-Wu Du, Ash A. Alizadeh, Jorg Goronzy, Cornelia M. Weyand, Eswar Krishnan, C. Garrison Fathman, and Holden T. Maecker. 2015. “Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging.” *PloS One* 10 (7): e0133627.
- Widjaja, Anissa A., Wei-Wen Lim, Sivakumar Viswanathan, Sonia Chothani, Ben Corden, Cibi Mary Dasan, Joyce Wei Ting Goh, et al. 2024. “Inhibition of IL-11 Signalling Extends Mammalian Healthspan and Lifespan.” *Nature* 632 (8023): 157–65.
- Wolf, F. Alexander, Philipp Angerer, and Fabian J. Theis. 2018. “SCANPY: Large-Scale Single-Cell Gene Expression Data Analysis.” *Genome Biology* 19 (1): 15.
- Wolock, Samuel L., Romain Lopez, and Allon M. Klein. 2019. “Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data.” *Cell Systems* 8 (4): 281-291.e9.
- Yang, Rui, Danielle T. Avery, Katherine J. L. Jackson, Masato Ogishi, Ibtihal Benhsaien, Likun Du, Xiaofei Ye, et al. 2022. “Human T-Bet Governs the Generation of a Distinct Subset of CD11chighCD21low B Cells.” *Science Immunology* 7 (73): eabq3277.
- Yang, Rui, Marc Weisshaar, Federico Mele, Ibtihal Benhsaien, Karim Dorgham, Jing Han, Carys A. Croft, et al. 2021. “High Th2 Cytokine Levels and Upper Airway Inflammation in Human Inherited T-Bet Deficiency.” *The Journal of Experimental Medicine* 218 (8). <https://doi.org/10.1084/jem.20202726>.
- Yasumizu, Yoshiaki, Daiki Takeuchi, Reo Morimoto, Yusuke Takeshima, Tatsusada Okuno, Makoto Kinoshita, Takayoshi Morita, et al. 2024. “Single-Cell Transcriptome Landscape of Circulating CD4+ T Cell Populations in Autoimmune Diseases.” *Cell Genomics* 4 (2): 100473.
- Zhang, Huimin, Rohit R. Jadhav, Wenqiang Cao, Isabel N. Goronzy, Tuantuan V. Zhao, Jun Jin, Shozo Ohtsuki, et al. 2022. “Aging-Associated HELIOS Deficiency in Naive CD4+ T Cells Alters Chromatin Remodeling and Promotes Effector Cell


Responses.” *Nature Immunology*, December. <https://doi.org/10.1038/s41590-022-01369-x>.

Zhang, Yong, Tao Liu, Clifford A. Meyer, Jérôme Eeckhoute, David S. Johnson, Bradley E. Bernstein, Chad Nusbaum, et al. 2008. “Model-Based Analysis of CHIP-Seq (MACS).” *Genome Biology* 9 (9): R137.

Zhu, Hongming, Jiawei Chen, Kangping Liu, Lei Gao, Haiyan Wu, Liangliang Ma, Jieru Zhou, Zhongmin Liu, and Jing-Dong J. Han. 2023. “Human PBMC ScRNA-Seq-Based Aging Clocks Reveal Ribosome to Inflammation Balance as a Single-Cell Aging Hallmark and Super Longevity.” *Science Advances* 9 (26): eabq7599.




**Figure 1. Generation of a high-resolution scRNA-seq atlas of peripheral immune cells from healthy children and adults.** **A.** Overview of the Human Immune Health Atlas cohort (age range: 11-65 yrs; n=108) and final reference dataset. **B.** UMAP of immune cell subsets within the Atlas, highlighting major immune cell populations. **C.** Log<sub>2</sub> fold change of clinical metadata features of age and CMV infection status compared using Milo differential abundance testing. Bronze is higher in older adults and Teal is higher in young adults. Red is higher in CMV<sup>+</sup> people and blue is higher in CMV<sup>-</sup> people. **D.** Marker gene expression and cell counts of the 71 immune cell subsets in level 3 of the Atlas. More details about this Atlas can be found at <https://apps.allenimmunology.org/aifi/resources/imm-health-atlas/>.



**Figure 2. Maintenance of age-related alterations in the healthy human immune landscape over time. A.** Overview of the longitudinal Sound Life cohort of healthy young ( $n=49$ ) and older ( $n=47$ ) adults. **B.** Volcano plot of the age-related protein expression differences in circulating plasma proteome at baseline (Flu Vax Year 1 Day 0). **C.** CXCL17 and WNT9A normalized


protein expression (NPX) over time in young (teal) and older (bronze) adult plasma. Each donors' samples are connected by a line. **D.** The number of differential expressed genes (DEGs) from DEseq2 analysis ( $\log_2fc > 0.1$  and  $p.adj < 0.05$ ) of immune cells subsets from young and older adults at 'Flu Vax Year 1 Day 0'. **E.** Bubble plot comparison of the change in frequency (using centered log-ratio (CLR) transformation) and number of DEGs at 'Flu Vax year 1 day 0' between young and older adults. Bubble size shows a combined metric of change defined as  $-\log_{10}(p.adj \text{ from CLR freq comparison}) \times \text{DEG\_Counts}$ . P.adj for CLR freq was determined using Wilcoxon rank-sum test with Benjamini–Hochberg correction. **F.** The RNA age metric, calculated as a composite score of the top upregulated DEGs for each subset with  $>20$  DEGs, shown across each donor at Flu Vax Year 1 Day 0. **G.** RNA age metric (upregulated genes) in select subsets over time in young and older adults. Each donors' samples are connected with a thin line. **H.** RNA age metric (downregulated genes) in select subsets over time in young and older adults. Each donors' samples are connected with a thin line.



**Figure 3. Dynamics of the healthy human immune landscape across age. A.** Overview of our follow-up cohort of healthy adults (n=234) ranging from 40 - 90 years of age. **B.** Normalized




protein expression (NPX) of select age- and inflammation-related serum proteins in our follow-up cohort, with donors ordered by age. **C.** UMAP of scRNAseq data generated from our follow-up cohort, totaling a final reference dataset of 3.2 million PBMCs. **C.** Distribution of immune cells by sex and CMV infection status with the UMAP. **D.** Composition of CD8 and CD4 T cell compartment across age. **E.** Frequencies (using centered log-ratio (CLR) transformation) of select T cell subsets within PBMCs across age. Regression line shown with 95% confidence intervals in gray. **F.** The average RNA Age Metric (upregulated genes) for the top age-impacted immune cell subset, shown across age. Regression line shown with 95% confidence intervals in gray. **G.** The average RNA Age Metric (downregulated genes) for the top age-impacted immune cell subset, shown across age. Regression line shown with 95% confidence intervals in gray. **H-I.** Heatmap of mean RNA expression by age in the follow-up cohort for select **H.** up-regulated and **I.** down-regulated genes identified from initial DEG analysis.




**Figure 4. Distinct impact of CMV infection and age on the immune landscape.** **A.** Bubble plot comparison of the change in frequency (using centered log-ratio (CLR) transformation) and number of DEGs at 'Flu Vax year 1 day 0' between CMV<sup>+</sup> (n=44) and CMV<sup>-</sup> (n=52) adults. Bubble size shows a combined metric of change defined as  $-\log_{10}(p.\text{adj from CLR freq comparison}) \times \text{DEG\_Counts}$ . **B.** Select subset frequencies in PBMCs shown over time. Teal dots are young adults. Bronze dots are older adults. Regression line shown. **C.** Representative flow plots of CD57 and NKG2C (*KLRC2* gene) expression within NK cells. Adaptive NKs cells are defined as CD57<sup>+</sup>NKG2C<sup>+</sup> NK cells. **D.** Adaptive NK cell frequencies and **E.** NKG2C (*KLRC2*) MFI expression on adaptive NKs comparing young CMV<sup>-</sup> (n=12), young CMV<sup>+</sup> (n=12),

older CMV<sup>-</sup> (n=12) and older CMV<sup>+</sup> (n=12) adults from spectral flow cytometry analysis. P-values calculated using unpaired Wilcoxon test. **F.** Heatmap of mean RNA expression levels from upregulated DEGs in adaptive NKs of CMV<sup>+</sup> young adults across all individuals in longitudinal cohort (n=96). **G.** *ZBTB38* expression in adaptive NKs (left panel) CMV<sup>+</sup> young (n=18) and older (n=24) adults, shown over time (up to 600 days after first blood draw). Teal dots are CMV<sup>+</sup> young adults. Bronze dots are CMV<sup>+</sup> older adults. Regression line shown. **H.** *ZBTB38* expression in adaptive NKs (right panel) CMV<sup>+</sup> (red, n=136) and CMV<sup>-</sup> (blue, n=98) adults across age in our follow-up cohort. **I.** Normalized expression (NPX-bridged) of plasma proteins in one young adult who converted from CMV<sup>-</sup> to CMV<sup>+</sup> over the course of our study. Proteins were considered significant if they had a 1.5 or greater fold change pre- to post-conversion. **J.** Normalized expression of GZMH protein in plasma of CMV<sup>-</sup> and CMV<sup>+</sup> individuals from our longitudinal cohort. Young and older adults are delineated by circle and squares, respectively. **K.** Normalized expression of GZMH protein in serum of CMV<sup>-</sup> and CMV<sup>+</sup> individuals from our follow-up cohort. P-value for J and K were determined by Wilcoxon rank-sum test. **L.** UMAP of GZMH RNA expression in PBMCs from all individuals in our longitudinal cohort. **M.** Dot plot of GZMH RNA expression in NK, CD4 T cell and CD8 T cell subsets.




**Figure 5. Age-associated B cell responses to the influenza vaccine.** **A.** Number of samples and sampling timepoints across 2 flu seasons in the young and older adult cohorts that received the same seasonal vaccines. **B-C.** B/Washington and **D-E.** B/Phuket flu-specific total IgG antibody expression (**B, D**) in plasma compared to expression at baseline (Day 0) for both young ( $n=26$ ) and older ( $n=42$ ) adult cohorts in Flu Vax Year 1 and Mean percent inhibition of flu hemagglutinin (HA) antigen as determined by the HAI assay (**C, E**) for both young ( $n=21$ ) and


older (n=22) adult cohorts at days 0 and 7 in Flu Vax Year 1. P-values were calculated using Wilcoxon's signed-rank test (paired) for the comparison between Day 0 and Day 7, and using the Wilcoxon rank-sum test for all other comparisons. **F.** Peripheral memory and antibody-secreting B cell population frequency changes in young (teal) and older adult (bronze) cohorts pre-vaccination (Day 0), and post-vaccination (Day 7). P-values determined by Wilcoxon's signed-rank test (paired). **G.** Enrichment plot for the top Hallmark pathway in CD27- effector B cells when comparing Day 7 transcriptome between young and older adults after gene set enrichment analysis. **H.** Sample level enrichment analysis scores for the Hallmark Reactive Oxygen Species Pathway at each timepoint for CD27- effector B cells in young and older adults. **I.** Volcano plot of DEGs for CD27- Effector B cells between the age cohorts at Day 7 post-vaccination. Highlighted genes are those previously shown to define a flu-specific effector B cell subset in a vaccinated adult cohort. Dark teal and bronze dots signify significantly different genes, and light-colored dots indicate nominal significance, while gray dots indicate no significance between age cohorts. **J-K.** Longitudinal expression of selected genes by CD27- effector B cell subset, averaged for each age cohort at each timepoint. **L.** Representative flow cytometry plot of CD19 and IgG protein expression on CD27- effector B cells in young and older adults at day 7 post-vaccination, based on flow cytometry analysis of 6 young and 6 older adult subjects that overlap with the scRNA data cohort. **M.** CLR-transformed frequency comparison of surface IgG+ CD27- effector B cells pre- and post-vaccination in young and older adults, as determined by flow cytometry. P-values were determined by Wilcoxon rank sum test with the alternative hypothesis 'less'. **N.** Median surface CD19 protein expression comparison on CD27- effector B cells pre- and post-vaccination in young and older adults, as determined by flow cytometry. P-values were determined by Wilcoxon rank sum test with the alternative hypothesis 'less'.



**Figure 6. Accumulation of an altered transcriptional state in central memory T cells with age.** **A.** Graphical representation of T cell and B cell interactions. **B.** Receptor-ligand interaction prediction between CM CD4 T cells and core memory B cells in young ( $n=47$ ) and older ( $n=49$ ) adults from a single time point (Flu Year 1 Day 0). **C.** CD40LG in CM CD4 T cells and CD40 in core memory B cells across age in our follow-up cohort ( $n=234$ ). Regression line shown with 95% confidence intervals in gray. **D.** Triangle plots of Th1-, Th2- and Th17- cell state scores in CM CD4 T cells from young (teal) and older (bronze) adults. **E.** Th2 cell state scores in CM CD4 T cells over time in young (teal) and older (bronze) adults. Regression line shown with 95% confidence intervals in gray. **F.** Triangle plots of Th1-, Th2- and Th17- cell state scores in CM CD4 T cells from our follow-up cohort ( $n=234$ ). **G.** GATA3 and TBX21 transcription factor (TF) activity based on ChromVar analysis of TEA-seq data in CM CD4 T cells from children ( $n=8$ ) and older adults ( $n=8$ ). **H.** Spearman correlation between GATA3 TF activity and Th2 cell state score in CM CD4 T cells from the TEA-seq dataset ( $n=16$ ). **I.** Chromatin accessibility tracks of the *IL4* gene region in CM CD4 T cell subsets, showing normalized read coverage.



**Figure 7. Age-related transcriptional states of central memory CD4 T associated with memory B cell response to influenza vaccination. A.** Arc plot of Th2 and Tfh cell states in CM CD4 T cells correlations with features of age, T cell - B cell interactions and B cell responses to flu vaccination. Only correlations with  $p_{val} < 0.05$  are shown. **B.** Select Spearman correlations of Th2 state with T-B interactions and B cell responses.



Figures 12



**Supplemental Figure 1**, in regard to Main Figure 2. **Impact of age, CMV infection and influenza vaccination on the healthy immune landscape.** **A.** Normalized protein expression (NPX) of inflammatory markers TNF, IL-6, IL-1b and IL-11 over time in young (teal) and older (bronze) adult plasma. **B.** Volcano plot of the age-related expression differences in circulating plasma proteome at baseline (Flu Vax Year 2 Day 0). **C.** Spearman correlation between age-related protein expression difference at Year 1 and Year 2. **D.** The number of down-regulated or up-regulated differential expressed genes (DEGs) from DEseq2 analysis of immune cell subsets from young (n=40) and older (n=44) adults at 'Flu Vax year 2 day 0' using DEseq2 analysis. **E.** Spearman correlation between the number of age-related DEGs in each immune cell subsets in 'Flu Vax year 1 day 0 and 'Flu Vax year 2 day 0'. **F.** The number of DEGs in immune cell subsets, comparing CMV (CMV-positive versus CMV-negative), Flu vaccination time series ("Flu Vax", Day 0 and Day 7 post-flu vaccination) and No Vax time series ("No Vax", Day 0 vs Day 7 after no vaccination) to that of age. DEGs were defined as  $\log_2fc > 0.1$  and  $padj < 0.05$  for all comparisons.

A


$$\text{Age Composite Metric}_i = \sum_{j=1}^n \frac{E_{ij} - \mu_j}{\sigma_j}$$

(Up or Down)


Where:

- Age Composite Metric<sub>i</sub> is the composite score for sample i.
- E<sub>ij</sub> is the mean pseudo-bulked expression for gene j in sample i.
- n is the total number of genes in the set, with n ≥ 20.
- μ<sub>j</sub> is the mean expression of gene j across all samples.
- σ<sub>j</sub> is the standard deviation of expression of gene j across all samples.
- The Age Composite Metric is calculated from genes that are differently regulated in older adults comparing with young adults. The 'Up' metric is based on up-regulated genes, and the 'Down' metric is based on down-regulated genes.


B



C




D




**Supplemental Figure 2, in regard to Main Figure 2. Maintained, age-related transcriptional signatures in healthy immune cell subsets. A.** Equation for calculating the composite age score in each immune cell subset with more than 20 DEGs between young and older adults. **B.** RNA age metric (upregulated and downregulated genes) in 8 subsets (all subsets with >20 DEGs) comparing young and older adults on year 1 day 0 samples. Each dot is from a single donor. P-value was determined using the Wilcoxon rank-sum test. **C.** RNA age metric (upregulated genes) in select subsets over time in young and older adults. Each donors' samples are connected with a thin line. **D.** RNA age metric (downregulated genes) in select


subsets over time in young and older adults. Each donors' samples are connected with a thin line.



**Supplemental Figure 3**, in regard to Main Figure 4. **Transcriptional landscape of healthy immune cell subsets altered by CMV and age.** **A.** Bubble plot comparison of the change in frequency (using centered log-ratio (CLR) transformation) and number of DEGs between CMV+ (n=136) and CMV- (n=97) adults in our follow-up cohort. Bubble size shows a combined metric of change defined as  $-\log_{10}(p.\text{adj from CLR freq comparison}) \times \text{DEG\_Counts}$ . **B.** Select subset frequencies in PBMCs shown over time. Teal dots are young adults. Bronze dots are older adults. Regression line shown. **C.** RNA age metric (upregulated genes) in select T cell subsets split by age and CMV infection status. P-values were calculated using Wilcoxon rank sum test. **D-E.** The number of DEGs ( $\log_2\text{fc} > 0.1$  and  $p.\text{adj} < 0.05$ ) in immune cell subsets comparing CMV+ and CMV- individuals, in young and older adults separately from our longitudinal cohort at **D.** 'Flu Vax year 1 day 0' and **E.** 'Flu Vax year 2 day 0'.



**Supplemental Figure 4**, in regard to Main Figure 5. **Age-associated responses of non-naive B cell subsets to flu vaccination.** **A.** Correlation plots of RNA-quantified (y-axis) and flow cytometry-quantified (x-axis) level 3 B cell population (individual plots) frequencies of total live PBMC. Data shown for 6 young and 6 older adult subjects in flu year 1 that were represented in both scRNA-seq and cytometry analyses. P-value and r values of the Pearson correlation are displayed. **B-D.** Sample level enrichment analysis (SLEA) scores for the top pathways in the Hallmark database at each timepoint for **B.** plasma cells, **C.** core memory B cells and **D.** CD27+ effector B cells in young and older adults.



**Supplemental Figure 5, in regard to Main Figure 6. Age-related transcriptional alterations in CM CD4 T cells independent from circulating cytokine signatures. A.** The CLR transformed frequency of ICOS+ CD38+ Tfh cells determined by spectral flow cytometry, at day 0 and day 7 post-influenza vaccination, comparing responses in young and older adults. P-values were calculated using Wilcoxon's signed-rank test (paired) for the comparison between Day 0 and Day 7, and using the Wilcoxon rank-sum test for all other comparisons. **B.** Tfh activity score was

determined by NMF projection in CM CD4 T cells in young and older adults. **C.** Expression of leading-edge genes in Tfh activity score in young and older adults. **D.** CXCR5 expression in CM CD4 T cells across age in our follow-up cohort. **E.** Receptor-ligand interaction prediction between CM CD4 T cells and core memory B cells in young (n=40) and older (n=44) adults from a single time point (Flu Year 2 Day 0). **F.** CD40LG expression in CM CD4 T cells in young and older adults. **G.** CD40 expression in core memory B cells in young and older adults. **H.** TEAseq UMAP of T cells based on RNA module, with CM CD4 T cells highlighted. **I.** IRF4 and STAT6 transcription factor (TF) activity based on Chromvar analysis of scATACseq data in CM CD4 T cells from children (n=8) and older adults (n=8). P-value was determined by Wilcoxon rank-sum or Wilcoxon signed-rank test, as appropriate, unless otherwise indicated in legend. **J.** Chromatin accessibility tracks of the *IL4R* gene region in CM CD4 T cell subsets from TEA-seq data, showing normalized read coverage. **K.** IL-4 normalized protein expression (NPX) in young (teal) and older (bronze) adult plasma. **L.** Normalized protein expression (NPX) of select Th1-, Th2- and Th17-related serum proteins in our follow-up cohort, with donors ordered by age.